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ABSTRACT 
 
Cutaneous leishmaniasis (CL) is a vector-borne neglected tropical disease caused by over 15 
species of the intracellular Leishmania parasite. This skin infection is the most common and 
widely distributed form of leishmaniasis, with an estimated 0.7-1.2 million new cases 
annually, mainly in the Middle East and Latin America. CL is rarely fatal, but the ulcerative skin 
lesions often leave lifelong scars, disfigurement, and social stigma. Current treatment of CL is 
far from optimal. The pentavalent antimonials remain the standard of care since their 
discovery in the 1940s, but typically require three weeks of painful, toxic injections into the 
lesions. An alternative therapeutic option is liposomal amphotericin B, but cure rates are 
variable, access is problematic and invasive drug administration is required. Basic research 
tools that could accelerate the successful discovery and development of much needed new 
drugs are currently limited. This thesis aims to provide a coherent set of R&D methodologies 
to evaluate (i) the penetration of drugs into the infected skin lesions (pharmacokinetics, PK), 
(ii) the ability to kill the causative Leishmania parasites (pharmacodynamics, PD) and (iii) the 
interaction between PK and PD (PK/PD) parameters. 
 In chapter 3.1, the limitations of the current in vitro models to predict in vivo drug 
activity were confirmed. Additionally, combination therapy of standard 
antileishmanial drugs with chloroquine was found unlikely to be a successful new 
treatment strategy for CL.  
 In chapter 3.2, we demonstrated a clear relationship between PK and PD parameters 
for the standard liposomal amphotericin B formulation AmBisome in a mouse model 
of CL, providing a PK/PD basis for the rational design of better clinical dose regimens.  
 In chapter 3.3, we compared the in vivo effects of AmBisome with Fungisome, an 
alternative liposomal amphotericin B formulation on the market in India. Fungisome 
was less efficacious than AmBisome due to lower drug accumulation in skin lesions 
and had a narrower therapeutic index in the treatment of murine CL.     
 In chapter 3.4, we showed that the CL infection and associated local skin inflammation 
has a profound effect on the PK of AmBisome and can contribute to its variable 
therapeutic efficacy against Old and New World Leishmania species. The increased 
vascular permeability of the dermal capillaries might be exploited for enhanced 
delivery of small (< 500 Da) oral drugs to the infected skin.  
 Finally, in chapter 3.5, we evaluated a new drug candidate from the Drugs for 
Neglected Diseases Initiative (DNDI) for visceral leishmaniasis. Our PK and PD data, 
based on innovative skin microdialysis and qPCR techniques, support the further 
preclinical development of the nitroimidazole DNDI-0690 as a promising new oral 
treatment for CL. 
 
Overall, the strategies, lessons and research tools provided in this PhD thesis could contribute 
to the development of safe, effective, affordable and patient-friendly new drugs for the 
treatment of CL.  
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1. GENERAL INTRODUCTION  
 
1.1. Leishmania species and leishmaniasis 
 
The leishmaniases are a group of vector-borne neglected tropical diseases, caused by over 20 
species of the protozoan Leishmania parasite that are transmitted to humans via sand flies. 
The disease mainly affects vulnerable, marginalized populations in Asia, Africa and Latin 
America and is associated with poverty, malnutrition, conflict, mass migration, poor housing 
and immunosuppression. Around 10 million present cases occur in over one hundred 
countries, the worldwide incidence is estimated at 1.5 million new cases per year and 350 
million people are at risk (1).  
A large fraction of infected individuals remain asymptomatic, but others develop one of the 
three main forms of the disease: visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) or 
mucocutaneous leishmaniasis (MCL).  
 VL, also known as kala-azar, is a potentially fatal infection of the liver, spleen and bone 
narrow caused by Leishmania donovani and Leishmania infantum. 200,000-400,000 
new cases occur annually, mainly in Brazil, Ethiopia, India, Bangladesh, Somalia, South 
Sudan and Sudan. Among the 20,000 to 30,000 deaths resulting from VL per year, 
many are children under five.  
 CL is characterized by disfiguring and disabling skin lesions and has the highest 
incidence (700,000-1,200,000) in the Middle East (Iran, Afghanistan, Syria, and Saudi 
Arabia, caused by the so-called ‘Old world’ Leishmania species) and South America 
(mainly Brazil, Colombia and Peru, caused by the so-called ‘New World’ Leishmania 
species).  
 In MCL, the lesions can lead to the partial or complete destruction of the mucous 
membranes of face, mouth and throat cavities. MCL is typically caused by Leishmania 
Viannia subgenus parasite species and over 90 % of cases occur in Bolivia, Brazil and 
Peru (2).  
 
Figure 1 shows an overview of the endemicity of pathogenic Leishmania species worldwide 
(3).  
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Figure 1: Geographical distribution of Leishmania in the Old (A) and New (B) World. Adapted from (3). 
 
1.1.1. Parasite life cycle  
 
Figure 2 summarizes the life cycle of Leishmania. Flagellated, extracellular Leishmania 
promastigotes are transmitted to humans via the proboscis (feeding apparatus) of infected 
female sandflies as they take a blood meal. After ingestion of the pathogen by macrophages 
(and to a lesser degree, other immune cells), the parasite transforms into its immobile, 
intracellular amastigote life stage within the phagolysosome. Parasite proliferation leads to 
host cell lysis and uptake by other phagocytes, causing and maintaining re-infection. When a 
naive insect bites an infected individual and takes a blood meal, the amastigotes transform 
to again promastigotes in the sand fly gut (4, 5).  
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Figure 2: Leishmania life cycle in humans (5) 
 
 
1.1.2. Vectors and transmission  
 
The vectors of transmission are tiny (2-3 mm), blood-feeding (female) insects called sand flies, 
of the genus Phlebotomus (in Asia, Africa and the Mediterranean Basin, ‘Old World’) and 
Lutzomyia (in the Americas, ‘New World’). The epidemiology of leishmaniasis is diverse and 
complex, with variations in types of sand fly vectors (6), transmission cycles (zoonotic and 
anthroponotic) (7), animal reservoirs (including dogs, mice and possums) (8), causative 
Leishmania species and environments (rural and urban) (9).  
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1.2. Cutaneous leishmaniasis (CL) 
  
1.2.1. Clinical manifestations 
 
Clinical features of CL vary in severity and outcomes, depending on factors relating to the 
host, the sand fly vector and the parasite. An overview of the taxonomy of Leishmania in 
relation to clinical manifestations is shown in figure 3 (10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Taxonomy of Leishmania in relation to clinical manifestations (10). 
 
Simple, uncomplicated CL (green in figure 3) is the most common form. It is characterized by 
disfiguring skin lesions on exposed body parts (face, arms, legs) which often self-heal within 
months to years. While rarely fatal, the resulting ulcers leave permanent scars, disability and 
stigma (11). Lesions and scars are associated with psychological and psychiatric conditions 
(depression, anxiety and low self-image), social exclusion (education, work and marriage) and 
an overall significantly lower quality of life (12, 13). The most common Old World (Middle 
East, Africa, Europe) species include L. major, L. tropica, L. aethiopica, while New World (the 
Americas) species include L. mexicana, L. amazonensis, L. panamensis and L. braziliensis.  
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The prevalence of complex CL is lower, but the related morbidity and mortality are far more 
severe. In leishmaniasis recidivans (LR, blue in figure 3), chronic ‘satellite lesions’ with a 
plaque-like appearance surround initially healing lesions. In diffuse CL (orange in figure 3), 
parasites disseminate through the skin and cause numerous non-ulcerated nodules. If the 
pathogen spreads to the mucosa of the nasal-oral cavity and/or laryngopharynx, a tissue-
destructive form called mucocutaneous leishmaniasis (MCL, purple in figure 3) can develop.  
An outsider in this array of skin pathologies is post-kala-azar dermal leishmaniasis (PKDL, 
yellow in figure 3), a cutaneous sequel after curing of VL (red in figure 3) (14). 
 
1.2.2. Immunopathology  
 
We will focus on the disease progression of a single CL lesion because it is the most common 
clinical presentation and the human disease phenotype that is mimicked in the animal models 
of infection.  Figure 4 gives an overview of the developmental stages of local CL (15). Single 
(or a limited number of) lesions form at the bite site of the parasite-infected female sand fly. 
A small papule forms, which develops into a nodule that forms a crusted ulcer. Eventually, 
after shedding of the crust and removal of the epidermis, an open wound with raised borders 
and crater-like appearance appears. Alternatively, non-ulcerative, erythematous nodules or 
crust-like plaques can occur.  
 
Figure 4: Disease stages in CL and involvement of the different layers of the skin (15) 
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Tissue damage and disease in CL are primarily caused by an excessive host immune response 
against the intracellular infection of macrophages by Leishmania (16). Figure 5 shows a 
hematoxylin-eosin (H&E) stain of a local CL skin lesion in the nodular stage of development. 
The intracellular amastigotes can be predominantly found within macrophages in the upper 
dermal layers of the lesion (figure 5, bottom left).  
As the dermis fills with a dense and diffuse mixed inflammatory cell infiltrate (including 
macrophages, lymphocytes, neutrophils, mast cells and plasma cells), the associated oedema 
drives swelling of the tissue (17, 18). Epidermal changes (hyperkeratosis, acanthosis and 
degeneration of the basal layer) and damage to the connective tissue damage (collagen 
matrix disruption) occur (19, 20). Healing of the lesion is associated with the generation of 
the appropriate immunological TH1-response and the related cytokines such as IFN-ɣ, TNF-α 
and IL-12 (21, 22): recruitment of leukocytes and activation of macrophages results in necrosis 
and the formation of generally non-caseating granuloma (23).  
 
 
 
Figure 5: Histology (H&E stain) of a single CL nodule on the arm of a patient (upper left).  The x 40  
magnification shows a dense inflammatory infiltrate within the dermal layer of the skin (right). 
Higher magnification (x 1250) reveals the intracellular Leishmania amastigotes (red arrows) within 
the phagolysosome of macrophages ( green arrows point at host cell nuclei) located in the upper 
layers of the dermis (derived from (20)). 
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1.2.3. Species-specific differences  
 
Figure 6 illustrates the clinical polymorphism of CL. The immunopathology of local CL shows 
both similarities (chronic, often ulcerative dermatosis) and differences (clinical presentation, 
incubation and resolution time) among different causative Leishmania species. For example, 
the anthroponotic Old World species L. tropica occurs in urban settings and is typically 
responsible for ‘dry’ (crusty, plaque-like) lesions, which slowly appears and cures over the 
course of 10-14 months (24). Zoonotic L. major is mostly found in rural villages and associated 
with larger, ‘wet’ (stronger inflammation and exudation) lesions that heal over 3-4 months 
(25, 26). Many New World form round lesions sometimes described as “weeping” or “pizza-
like”, such as L. braziliensis (27, 28). L. mexicana often causes chronic “Chiclero’s ulcers” on 
the face or ear, which resolve over months, up to years (29, 30).  In this work, we have used 
two mouse models of CL: Old World L. major-BALB/c and New World L. mexicana-BALB/c.  
   
 
 
Figure 6: Clinical polymorphism of CL caused by different Leishmania species (14, 24-30). 
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1.3. Current treatment of CL 
 
In contrast to VL, CL is rarely a fatal disease. However, the skin lesions and resulting scars 
cause considerable morbidity due to social stigma and psychological burden. In addition, the 
economic impact on individuals and communities in endemic areas is significant (11-14). The 
primary goal of treatment is to eliminate the causative parasites to accelerate wound healing 
and reduce the risk of scarring, while also preventing relapses, parasite dissemination and 
secondary infections. From an epidemiological and public health point of view, treatment of 
the patient reservoir is important to limit further transmission of the disease (31).  
There is no universally applicable therapy for CL: the drug, dose and duration depend on 
factors such as the parasite, the host and the clinical presentation. The World Health 
Organization (WHO) has specific recommended clinical regimens based on the diagnosed 
parasite species (32-35) and different treatment guidelines for CL in the New (36) and the Old 
(37) World. Treatment can consist of (i) chemotherapy (direct killing of the parasite with 
antileishmanial drugs), (ii) local physical treatments (exposure of the thermosensitive 
pathogens in the skin to cryo- or thermotherapy) or (iii) immunotherapy (modulators that 
induce a host effector immune response against Leishmania) (38).  
Figure 7 shows the current treatment strategies for the different forms of CL and their 
limitations. The available chemotherapeutics can be divided into systemic (transport of the 
drug to the infected skin via the blood) or local (direct application of a topical formulation to 
the lesion) treatments. Local treatment is attractive for the management of mild disease and 
has the potential advantages of reduced systemic toxicity, outpatient care, ease of use and 
high drug exposure at the site of action (the infected dermis underneath the skin lesions). 
Systemic treatments (injections or oral formulations such as tablets) come at a higher risk of 
adverse effects and are typically reserved for patients with more severe disease (3), including:  
 Large (> 5 cm), multiple (>4) or disseminated lesions 
 Disabling and immobilizing lesions (joints, feet) 
 Disfiguring and mutilating lesions on cosmetically sensitive areas where the 
application of local treatments is challenging (face, lips, ears, eyes) 
 Lesions that do not respond to local treatment 
 Lesions caused by parasites associated with the risk of mucosal (many Leishmania 
Viannia species), chronic (L. tropica) or diffuse (L. aethiopica) syndromes.  
 Immunosuppressed patients  
 
In some cases, treatment is not required. Many simple CL cases with small (< 1 cm), 
uncomplicated, single lesions self-heal over a couple of months. Therefore, there can be a 
negative risk-benefit ratio to expose patients to the currently available drugs, many of which, 
as the following sections will show, have major limitations: variable efficacy, considerable 
toxicity, invasiveness or high cost (39).  
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Figure 7: Treatment strategies for the different forms of CL and their limitations (39). Syst=systemic. 
Tx= treatment. ACL=asymptomatic CL.  
 
 
1.3.1. Systemic chemotherapeutics  
 
1.3.1.1. Pentavalent antimonials 
 
Pentavalent antimonials (SbV) have been the standard of care for CL since their development 
in the 1940s (40). Sodium stibogluconate (Pentostam®, GSK and generics) contains 100 mg/ml 
SbV , whereas meglumine antimoniate (Glucantime®, Sanofi) contains 85 mg/ml (figure 8) 
(41). The drugs are typically administered via injections into the edges of the skin lesions (~ 1-
1.5 ml, every 2-3 days for up to 2-3 weeks), with or without supplementary thermo- or 
cryotherapy. These SbV injections are associated with local inflammation, burning sensations 
and malaise and many patients struggle to complete treatment (32). In complex CL, 
antimonials can also be administered systemically (intramuscularly or intravenously at 20 
mg/kg daily for 10-20 days), but close clinical monitoring is required due to the risk of hepatic- 
and cardiotoxicity (10). While there is some evidence for the efficacy of pentavalent 
antimonials in CL, large, high quality and placebo-controlled randomized clinical trials are 
lacking (36, 37).  In addition, therapeutic outcomes vary in the different endemic regions of 
CL. In vitro studies confirmed variable in vitro susceptibility of Leishmania species to SbV (42, 
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43). In addition, in a clinical trial in Guatemala, the cure rates after treatment with 
Pentostam® were higher for L. braziliensis compared to L. mexicana CL (44).    
Despite being used against leishmaniasis for over seven decades, the molecular and cellular 
mechanism(s) of action of the antimonials remain poorly understood. Three models have 
been proposed. The prodrug model states that SbV is reduced by macrophages or amastigotes 
to a much more toxic/active metabolite, the trivalent form (SbIII ). This interferes with the 
redox homeostasis by inhibition of the trypanothione reductase system and leaves the 
parasites vulnerable to oxidative stress (45, 46). Alternatively, DNA fragmentation could lead 
to apoptosis of the pathogen (47). According to another model, SbV exerts intrinsic 
antileishmanial activity by inhibition of type I DNA topoisomerase, leading to a depletion of 
intracellular ATP and reduced biosynthesis of macromolecules. A final model postulates that 
antimonials clear intracellular Leishmania via activation of the host immune system (48).  
The pharmacokinetics of sodium stibogluconate in CL after intramuscular administration to 
patients are characterized by relatively rapid and complete drug uptake into the skin lesions, 
albeit slower and lower than in blood. Comparing affected and healthy skin, the CL infection 
does not seem to have a major influence on SbV accumulation at the target site (49).  The PK 
profile of SbV could be described by a one-compartmental model with a volume of distribution 
(Vd) of 45.7 l, a plasma half-life (T1/2) of 9.5 h and a renal clearance of 12.7 l/h.  Analysis of 
distribution patterns of area-under-curve (AUC) among patients suggested the existence of 
rapid and slow drug eliminators, partly explaining the variability in therapeutic response after 
antimonial treatment of CL (50).    
 
 
Figure 8: Chemical structure of sodium stibogluconate (PentostamTM, left)  and meglumine 
antimoniate (GlucantimeTM, right). Pentavalent antimonials typically require three weeks of painful 
injections into the lesions (photos). 
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1.3.1.2. Miltefosine  
 
Miltefosine (MF, figure 9), is an alkylphosphocholine and the only oral drug available for the 
treatment of leishmaniasis. It is used in VL and complex cases of CL (2.5mg/kg/day for 28 days) 
(51)). Phospholipids such as MF were originally developed as anti-cancer chemotherapeutics, 
but their antileishmanial activity was discovered in the 1980s (52).  The efficacy of MF varies 
among CL-causing parasite species, explaining variability in clinical settings.  Cure rates in 
randomized clinical trials in Colombia were 91 % against L. panamensis (38% in placebo 
group), while those in similar studies in Guatemala were only 53 % against L. mexicana and L. 
braziliensis (32 % in placebo group) (53). In Iran, the efficacy of MF against L. major was similar 
to that of intramuscular meglumine antimoniate (81%) (54). In vitro laboratory studies 
confirm intrinsic differences in drug susceptibility among Leishmania species (55). 
The mode of action of MF against Leishmania is currently unclear. Direct interaction with the 
parasite membrane (56), inhibition of phospholipids synthesis (57), mitochondrial 
dysfunction (58) and induction of apoptosis-like cell death (59) have been proposed. 
While the registration of MF in India as the first oral antileishmanial in 2002 was considered 
a breakthrough in the treatment of VL, access today in various regions of endemic for CL 
remains problematic. Shortages due to faulty supply chains, substandard generic 
formulations and variable prices ($ 50-200 in many developing countries, up to $ 10000-50000 
in the EU and the USA) cause issues related to availability and affordability (60).  
In terms of pharmacokinetics (PK), MF is the most-studied drug in CL pharmacotherapy. A PK 
clinical trial in Colombia revealed that overall MF exposure (AUC) in children was significantly 
lower than in adults, while in vitro susceptibility of the parasites (predominantly L. 
panamensis) was similar in both groups. Thus, optimized treatment regimens for CL in 
pediatric populations might be required (61, 62). The PK of MF is characterized by high protein 
binding properties (>95%), its exclusive metabolism by phospholipase D and very slow 
removal from the body (T1/2 = 7 days, total elimination after 31 days). This last property causes 
concern for its general therapeutic use in elimination programs, due to the teratogenicity and 
the risk of the emergence of resistance. Moreover, while this oral drug is generally relatively 
well-tolerated, gastrointestinal side effects such as vomiting and diarrhoea are common (63).  
 
Figure 9: Miltefosine - chemical structure and capsules 
   
 
12 
 
1.3.1.3. Amphotericin B  
 
Amphotericin B (AmB, figure 10) is a polyene antibiotic used in the treatment of leishmaniasis. 
AmB is mainly reserved for complex cases of CL (such as MCL) and is administered via slow 
intravenous infusion of deoxycholate (0.7 mg/kg/day for 25-30 days) or liposomal 
formulations (2-3 mg/kg/day for a total dose of 20-40 mg/kg) (32).  
AmB was discovered in the 1950s as a macrolide derived from Streptomycete cultures with 
potent antifungal activity. It was licensed and introduced on the market in 1959 as a sodium 
deoxycholate solution (DAmB, for intravenous use) that forms a micellar suspension when 
reconstructed in saline. DAmB remained the gold standard for invasive fungal infections for 
decades. However, this formulation suffers from dose-limiting nephrotoxicity and fever, 
anaemia, malaise and abdominal pain side effects (64).  
To overcome such issues, different new formulations based on lipid carrier systems with 
reduced toxicity have been developed since the 1990s. These include lipid complexes 
(Abelcet) colloidal dispersions (Amphocil) and liposomes (AmBisome, Fungisome) (65). 
AmBisome (LAmB), a unilamellar liposome marketed by the pharmaceutical company Gilead 
Sciences (US), has a superior efficacy and safety profile than conventional AmB and has been 
commercially the most successful (66). However, the cost (up to $ 250 per vial) and 
challenging logistics (cold chain) severely hamper access to LAmB in many primary health care 
settings (67). In 2016, a partnership between Gilead and WHO resulted in a $ 20 million drug 
donation over 5 years for the treatment of VL (68).  
As is the case in fungi, the mode of action against Leishmania is related to complexation of 
the drug’s hydrophobic polyene region with ergosterol in the plasma membrane of the 
pathogen. After binding, pores are formed that cause a collapse of ion gradient and 
consequent death of the parasite (69, 70). Recent research has suggested an alternative 
mechanism: large, extramembranous aggregates of AmB extract ergosterol out of the lipid 
bilayers, rather than forming channels within them (71). Interestingly, AmB also exerts 
immunomodulatory effects. After binding to Toll-like receptors, it induces oxidative stress in 
immune cells (including macrophages, neutrophils, natural killer cells, B-cells and T-cells) and 
alters expression of several cytokines and chemokines leading to (predominantly) pro-
inflammatory responses (64, 72, 73).    
The activity of the different lipid formulations of AmB has already been compared in the L. 
major-BALB/c mouse model of CL: the efficacy of AmBisome was superior to that of Abelcet 
and Amphocil. However, in vitro activity was higher for Amphocil than for AmBisome and 
Abelcet (74, 75). The pharmacokinetics of DAmB and LAmB differ greatly, as shown by studies 
in both rodents (76, 77) and humans (78, 79). After IV administration, DAmB reaches the 
peripheral tissues more rapidly than LAmB, but its systemic circulation is shorter for the non-
liposomal form. In contrast to DAmB, with its narrow therapeutic margin, LAmB can achieve 
high yet safe plasma and tissue levels (80). Elimination patterns from the body are similar for 
both formulations, with a tri-phasic kinetics and a primary plasma half-life of around 6 hours.   
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The underlying pharmacological and physiological mechanisms that could explain the variable 
therapeutic outcomes of different pharmaceutical formulations of AmB in CL were 
investigated in chapters 3.2, 3.3 and 3.4.  Please note the similar and possibly confusing trade 
names of AmB deoxycholate (Fungizone) and the multilamellar AmB liposome (Fungisome).   
 
 
Figure 10: Amphotericin B – chemical structure and the different formulations AmBisome® 
(unilamellar liposome of AmB), Fungisome ® (multilamellar liposome of AmB) and Fungizone® 
(deoxycholate salt of AmB) for intravenous infusion. 
 
 
1.3.1.4. Pentamidine   
 
Pentamidine (figure 11), a synthetic derivate of amidine, is a systemic second-line drug for 
New World CL, specifically for L. guyanenesis and L. panamensis (32). It has also been used to 
treat Pneumocystis carinii infections in AIDS patients and sleeping sickness. The drug is 
administered as an isethionate salt via the intramuscular or intravenous route at 4 mg/kg 
(salt) every other day for 3 doses (81, 82). The mechanism of action is poorly understood, but 
interference with Leishmania DNA synthesis and the mitochondrial membrane have been 
suggested. The pharmacokinetics of the drug are best described by a 2- or 3-compartmental 
model, with rapid and extensive tissue distribution, predominant hepatic metabolism and 
biliary clearance. No data is available on drug accumulation in the skin. Pentamidine has been 
progressively abandoned in the treatment of leishmaniasis due to severe adverse effects 
including shock, hypoglycemia, diabetes mellitus, myocarditis and nephrotoxicity (62). 
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Figure 11: Pentamidine – chemical structure 
 
1.3.1.5. Azoles  
 
Fluconazole and ketoconazole (figure 12) are oral imidazole antifungals that are also used in 
the 2nd-line treatment of CL. There is some evidence to recommend fluconazole for L. major 
therapy (200 mg oral, daily for 6 weeks) and ketoconazole for L. mexicana and L. panamensis 
(600 mg oral, daily for 28 days) (32). However, overall clinical experience with these drugs in 
CL remains limited: a recent systematic review concluded there is insufficient evidence to 
support the use of azole therapy as a single agent for leishmaniasis treatment (83). The 
mechanism of action against Leishmania is identical as for fungi: inhibition of ergosterol 
synthesis, leading to cell membrane instability and death. Adverse effects of azoles include 
gastrointestinal symptoms and hepatic toxicity (62). Interestingly for the treatment of CL, 
fluconazole concentrations in plasma and dermis after oral dosing are similar and exposure 
in the skin is prolonged due to a high binding affinity for the stratum corneum (84, 85). 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Fluconazole (left) and ketoconazole (right) – chemical structure 
 
 
 
 
 
   
 
15 
 
1.3.2. Local chemotherapeutics  
 
1.3.2.1. Paromomycin  
 
Paromomycin (PM, figure 13), also known as monomycin or aminosidine, is a broad spectrum 
aminoglycoside antibiotic. PM is used as a sulfate salt in the treatment of both VL (11 mg/kg 
for 21 days, IM) and local, simple CL (15% PM + 12 % methylbenzethonium chloride (MBCL) 
ointment twice daily for 20 days, topical) (32).  The majority of CL patients are treated with 
Leishcutan® (Teva, Israel), the only commercially available ointment of topical PM (86).  
WE279,396 is an experimental, more hydrophilic cream containing 0.5% gentamycin in 
addition to 15 PM % (87). The antileishmanial activity of PM was discovered in the 1960s (88). 
In the 1980s, El-On and colleagues demonstrated the excellent efficacy of PM against L. major 
after intraperitoneal (50 mg/kg daily for 10 days) and topical (2x daily for 10 days) drug 
administration in mice (89), followed by promising results in humans (90). Topical 15% PM + 
12% MBCL was also active in mice infected with New World species such as L. mexicana, but 
inactive against L. panamensis and L. amazonensis (89). A meta-analysis of 14 randomized 
trials concluded that topical PM+MBCL could be a therapeutic alternative to antimonials in 
uncomplicated Old World CL, while no existing data support use in New World CL (91). Clinical 
trials for WE279,396, with or without gentamycin, failed to show an increased cure rate 
compared to placebo.   
The exact antileishmanial mode of action for PM is poorly understood.  Research has 
suggested inhibition of protein synthesis (92), energy metabolism (93) and vesicle-mediated 
cellular trafficking (94).     
Penetration of topically applied PM into the skin lesion is challenging: the large (molecular 
weight = 714 g/mol), hydrophilic compound requires quaternary ammonium compounds such 
as MBCL to enhance permeation across the epidermis. Unfortunately, MBCL is also the 
responsible agent for local irritation and side effects. Some clinical trials (87) give a misleading 
representation of the skin pharmacokinetics of topical PM, for example by manual removal 
of the crust or wound debris from the lesion, exposing the infected dermis directly. In patients 
with CL treated once daily for 20 days with topical PM creams with or without gentamycin, 
the estimated dose absorbed was 10-12 % and systemic exposure is limited (Cmax = 0.6-1 
µg/ml) (95). Little is known about the differences in skin penetration of PM formulations in 
early closed nodules with intact skin, crusted lesions with early skin damage or open 
ulcerative wounds, or how to best use topical treatments for the different disease forms of 
CL in general.  
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Figure 13: Paromomycin – chemical structure and ointment 
 
1.3.3. Physical treatments  
 
Thermo- and cryotherapy are physical therapies with the aim to eliminate the CL-causing 
parasites by temperature rather than by chemotherapy. This could overcome many of the 
limitations of antileishmanial drugs, which are related to adherence, cost, contraindications 
and side effects (32). In thermotherapy, heat is induced in the superficial skin layers by 
ultrasound, radiofrequency or infrared radiation. Typical treatment involves 30 seconds of 
exposure at 50 °C once per week for one month (96, 97). During cryotherapy, a cotton swab 
dipped in liquid nitrogen is applied to the lesion for 10-25 seconds for several weeks (98). A 
recent meta-analysis of 8 randomized trials showed that thermotherapy is not inferior to 
intralesional antimonials and the two could be used in combination for the treatment of CL 
(99). Issues related to these treatments include the need for expensive equipment, trained 
staff and electricity, which could be an issue in the remote CL-endemic regions. 
 
1.3.4. Immunotherapy  
 
Immunotherapy could be a useful adjunct to chemotherapy to stimulate the host immune 
response to clear the parasite from the system (100). Imiquimod is an imidazoquinoline 
immunomodulator that is on the market for the treatment of genital warts as a topical cream 
called Aldara (Meda Pharma, UK). During a phase II trial for CL in Peru, it was found to be safe, 
enhance the efficacy of pentavalent antimony and reduce scarring (101). Cytokine 
granulocyte-macrophage colony stimulating factor (GM-CSF) is another topical 
immunomodulator that supports wound healing. In Brazilian CL patients, GM-CSF in 
combination with antimonials reduced the healing time of lesion compared to antimonials 
alone (102). 
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1.4. Treatment challenges in CL  
 
CL is one of most neglected of the neglected tropical diseases (NTD), an umbrella term for a 
diverse group of infectious diseases that affect around 2.7 billion people living on less than $ 
2 per day (103, 104). This causes a number of major issues for treatment, which, as the 
previous section has shown, currently relies on drugs that are considerably toxic, poorly 
tolerated, variably effective in different endemic settings or invasive in terms of 
administration route. These challenges include: 
 
 The economic reality of pharmaceutical research into NTDs. Overall, the main 
challenge for finding new CL treatments is to ensure that the disease is actually on the 
drug research and development (R&D) agenda and that the necessary leadership, 
strategy and expertise are provided. Development of a new drug is typically a long (10-
15 years) and expensive process: the actual costs is a controversial topic and estimates 
range widely from $ 92 to $ 888.6 million (105-107). Medicines for NTDs are not 
attractive targets for the profit-driven pharmaceutical industry, as the ability-to-pay 
of both patients and the healthcare systems is low (60). Unfortunately, without 
investment, there is no research and thus no new drugs. To make matters more 
complex, CL is not a single disease (LCL, MCL, DCL, LR) and is not caused by a single 
parasite (over 15 different Leishmania species, with known variability in drug 
susceptibility). Identifying one drug active against all types of CL is not a simple 
mission, but if the lucrative market size is smaller, the chance of capturing the interest 
of major pharmaceutical companies becomes even more limited. Repurposing and 
reformulation of existing drugs are common strategies to overcome the high costs of 
de novo drug discovery for NTDs (108), including CL. Indeed, the 2nd-line drugs MF, PM 
and AmB were originally developed as agents against cancer and bacterial and fungal 
infections, respectively. 
 Access to treatment. Even if government-funded programs provide CL treatment for 
free or at a reduced cost, many of the affected people delay their visit to the clinic 
because health facilities are far from their communities and travel is difficult or 
expensive (11). This could cause patients to only present in the hospital after local, 
home-made, or herbal remedies have failed and when lesions are far-advanced and 
often harder to treat. Additionally, the long duration of therapy, such as the three 
weeks required for antimonial treatment, keeps them away from work and their 
ability to provide for their family. In the health care centre, the direct costs of 
diagnosis, treatment, hospitalization and drug administration add to overall 
expenditure, contributing to the perpetuation of a vicious cycle of poverty (109). 
 The hidden true burden of CL. Because the disease often occurs in marginalized 
populations living in remote areas, the current epidemiological numbers are likely 
underestimates of the actual prevalence and incidence. According to WHO, CL is only 
a reportable disease in 40 out of 88 countries where it is considered endemic (2). 
Moreover, much of the burden of CL is mainly socio-psychological in nature, making 
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direct quantification of its impact more challenging (11). As a result, overall efforts 
from authorities for the control of CL, such as stimulating the search for better 
treatments, are limited.  
 Logistics. Access to diagnostics and medicines in remote health care centres can be 
problematic, as can be the thermal stability of drugs and pharmaceutical formulations 
in tropical climates (110). 
 The standardization and quality of clinical trials. Many studies are poorly designed 
and conducted on a small number of participants that are variably diagnosed in terms 
of Leishmania species (while there are known differences in drug susceptibility) and 
unclear in defining treatment outcomes (which is extremely problematic for an often 
self-healing disease). Systematic reviews on CL treatments pointed out these issues: 
Olliaro and colleagues formulated methodological guidelines for a clinical trial for CL 
(111, 112). Such standardized, randomized and controlled clinical studies are required 
to evaluate what therapeutic interventions work and are safe for patients. But first, 
we will need new drug candidates to actually be tested in such studies.   
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1.5. Drug development for CL 
 
1.5.1. Drug discovery and development  
 
Drug discovery and development is a slow, costly and challenging process. As explained 
before, for every 100000 compounds screened, only one might make it out of the research 
and development (R&D) pipeline as a marketed drug, after at least 10 years and an 
expenditure as high as $ 2.6 billion (113). Figure 14 gives an overview of the classic drug 
discovery and development process. During the ‘hit-to-lead’ drug discovery phase, an 
extensive list of ‘hits’ against a specific target is identified within a library, from which ‘leads’ 
with the most suitable profile are selected. Leads are tested in terms of activity, safety, 
metabolism and PK and can be optimized by chemical modification. When a drug candidate 
is finally selected, the compound is characterized in depth during preclinical development 
studies. After clinical research in humans (phase I, II and III) and regulatory agency approval, 
the new medicine reaches the market and its safety in the wider population is surveilled 
(phase IV) (114). However, attrition rates of new compounds in drug development are high: 
more than half of the drug candidates fail during clinical trials due to a lack of efficacy, another 
third due to safety issues and narrow therapeutic index (115). Our poor ability to translate 
our advances in the biological understanding of human disease into effective new 
therapeutics and the many failures along the R&D process has been coined as the notorious 
“valley of death” of drug development (116).    
 
 
 
Figure 14: The classic drug discovery and development pathway (116) 
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Improving the likelihood of clinical success requires the availability of validated predictive 
models, assays and methodologies during discovery and preclinical development phases. 
These are tools for screening and evaluation of hits, leads and drug candidates based on 
specific criteria (117, 118). Setting clear and well-considered go/no-go criteria are crucial to 
focus time and resources on new chemical entity (NCE) series that stand a reasonable chance 
of delivering a potential new medicine (119).  
This is especially important for drug development for infectious diseases that 
disproportionally affect populations in the developing world, where financial incentives are 
limited. Today, two contrasting trends are present in the global infectious disease market: on 
the one hand, there is an unprecedented growth for the antiviral (hepatitis C, HIV) and vaccine 
areas. On the other, the antibiotic market has been in decline for decades (120). Annual 
revenues for antibacterial agents dropped from $ 15 to $ 8 billion between 2010 and 2017, 
due to generic competition and limited innovation in the pipeline (121). Indeed, anti-
infectious drug R&D is a therapeutic problem area, due to scientific challenges, regulatory 
hurdles and low return on investment: a worrying trend in an era of rising antimicrobial 
resistance. In recent years, many pharmaceutical companies have been gradually reducing 
their commitment to this field; some, such as Astra Zeneca, even pulled out entirely (122).  
Among the infectious diseases, NTDs are a particularly commercially unattractive area for 
R&D. The overall pipelines for NTDs remain weak and chances that many new drugs for the 
treatments leishmaniasis, Chagas disease, sleeping sickness or helminthiasis will soon flood 
the market are minimal (123). Figure 15 shows the number of projects at each stage of 
discovery and development in 2009. 
 
  
 
Figure 15: Attrition rate and current R&D pipeline for (neglected) tropical diseases. HAT = Human 
African Trypanosomiasis (sleeping sickness). TB = tuberculosis. Adapted from (123).  
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However, events in recent years have given us reasons for cautious optimism. 
Around the beginning of the new millennium, public-private partnerships (PPP) such as 
Medicines for Malaria Venture, Institute for One World Health, Global Health Innovative 
Technology Fund, TB Alliance and Drugs for Neglected Diseases Initiate (DNDI) emerged (124). 
These small-to-medium-sized organizations bring together partners from academia, the 
pharmaceutical industry and the public sector and provide the flexibility and efficiency to 
quickly move new medicines through the R&D pipeline (125). Since 2003, DNDI has developed 
seven new treatments and formulations for malaria, pediatric HIV, sleeping sickness, Chagas 
disease and VL (126). However, a lack of sustainable funding and direct impact evaluations 
threaten the long-term viability of PPP as a business model to develop new drugs, vaccines 
and diagnostics for NTDs (127). 
Two important events occurred in 2012. The WHO’s roadmap “accelerating work to overcome 
the global impact of NTDs” produced a shared commitment with global pharmaceutical 
companies to contribute to the control of these diseases of poverty (128). Building on this 
momentum, the “London Declaration on NTDs” was signed later that year by officials of 13 
leading multinational pharma companies, the World Bank, WHO, the Bill & Melinda Gates 
Foundation and governments from endemic and non-endemic countries. Partners committed 
to advancing R&D for NTDs by 2020, in addition to expanding and sustaining drug access and 
donation programs (129).   
Finally, 2015 saw the birth of the “Neglected Tropical Diseases Drug Discovery Booster”, a 
consortium with the aim to accelerate, expand and reduce the costs of early-stage drug 
development for Chagas disease and leishmaniasis. This global collaboration brought 
together DNDI and six pharmaceutical companies ((Eisai Co Ltd, Shionogi & Co Ltd, Takeda 
Pharmaceutical Company Limited, AstraZeneca plc., Celgene Global Health and Merck KGaA) 
to identify new potential anti-parasitic agents in one other's compound libraries (130).  
 
1.5.2. R&D pipeline for CL   
 
In recent years, academic researchers from around the world have identified a plethora of 
compounds with antileishmanial activity. Some are repurposed (tamoxifen, nelfinavir, 
imipramine, delamanid, fexinidazole), others are derived from natural products (quinones, 
pyrimidines, diamidines) and there are novel scaffolds from phenotypic screens (131). The 
public-private partnership DNDI has a number of new drug candidates in its pipeline for CL 
(132, figure 16). These novel candidate treatments include: 
 Immunotherapy. CPG-D35 oligonucleotides are synthetic, single-stranded DNA 
molecules that activate immune cells in the skin that could be used alone or in 
combination treatment for CL. Currently in the preclinical phase. 
 New combinations of current CL therapeutics. Three weeks of oral miltefosine is 
currently being tested with or without a single application of thermotherapy (30 
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seconds at 50 °C) on patients in Peru and Columbia. This could improve efficacy, 
reduce side effects and shorten the duration of treatment.   
 Three chemotherapeutic lead series with oral bioavailability and excellent activity in 
cellular and animal models of leishmaniasis have been identified: 
  
1. Aminopyrazoles, originally explored by Pfizer for the treatment of cancer. 
Compounds of this class, such as DNDI-5561, are currently in  preclinical 
phases.  
2. Oxaboroles (cyclic, boron-containing drugs), initially identified for their 
antifungal potential by Anacor Pharmaceuticals and developed by DNDI for 
the human African trypanosomiasis (HAT) and extended to Chagas Disease 
and leishmaniasis. SCYX-7158 is in clinical phase II/III for HAT, while DNDI-
5421 and DNDI-5610 are in the lead (optimization) phases for 
leishmaniasis. DNDI-6148 has recently entered clinical phases.  
3. Bicyclic nitroimidazoles DNDI-8219 and DNDI-0690 (clinical candidate), 
from a tuberculosis library,  show excellent in vitro activity and in vivo 
efficacy against VL and CL. Results for another compound, DNDI-VL-2098, 
were initially promising, but development was discontinued due to 
observed testicular toxicity.  
 
 
 
 
Figure 16: R&D pipeline for leishmaniasis (June 2018, DNDI, 132) 
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The British pharmaceutical company GlaxoSmithKline, in partnership with the Drug Discovery 
Unit of the University of Dundee, is collaborating with DNDI on two new chemotherapeutic 
compounds (GSK3186899/DDD853651 and GSK3494245/DDD1305143) that are currently in 
preclinical phases of drug development for VL.  Finally, apart from DNDI and GSK, the Swiss 
multinational pharmaceutical company Novartis also has a leishmaniasis portfolio. GNF6702, 
a selective kinetoplastid proteasome inhibitor, is a promising drug candidate for 
leishmaniasis. In mouse models of VL, the compound demonstrates excellent in vivo activity, 
does not inhibit the mammalian proteasome and is well tolerated at therapeutic doses. Even 
more exciting is the fact that the molecular proteasome target is conserved among 
kinetoplastid parasites and GNF6702 is also active against Trypanosoma cruzi and 
Trypanosoma brucei. This gives rise to the possibility of a single class of drugs to treat not only 
leishmaniasis but also Chagas disease and sleeping sickness (133).     
While the current R&D pipeline is promising and gives genuine hope for delivering new 
therapeutics for CL, it is important to remember the sobering attrition rates during the early 
phases of clinical trials. Therefore, continuous drug discovery efforts and the availability of 
suitable backup candidates is critical to maximizing the chance of bringing new, safe and 
effective treatment to patients in the near future (134). 
 
1.5.3. Profile of an ideal CL drug 
 
An ideal new treatment for CL would be safe in all populations, efficacious against all 
Leishmania species, affordable, feasible for use in the field, be of a short time course and be 
available in an easy-to-use formulation, such as a tablet or a local topical (cream, ointment, 
spray). Optimal pharmacotherapy may well be a combination of two or more agents 
(chemotherapy with or without complementary immunomodulators) to maximize efficacy or 
safety and to minimize treatment duration or the risk of the emergence of antileishmanial 
drug resistance. Target product profiles play a central role in the entire drug development 
process to provide focus and facilitate decision-making.  An example of a target product 
profile for CL used by DNDI is shown in table 1 (135).    
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Table 1: Target product profile for CL (DNDI) 
 
 
 
 
1.5.4. Introduction to the pharmacology of CL drugs  
 
Antileishmanial drug activity in CL is the result of a complex interaction between three 
pharmacological actors, namely the active drug in the pharmaceutical drug formulation, the 
Leishmania parasite and the host cells and tissues. Figure 17 gives an overview of these 
relationships. 
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Figure 17: Actors and relationships in the anti-parasitic activity of a CL drug 
 
 Infection and pathology kinetics describe how the presence of the parasite within the 
phagolysosome of the dermal macrophages affects the host, resulting in skin lesions. 
In CL, pathology and disease is mainly the consequence of an excessive host immune 
response against the pathogen: a severe local inflammation and associated oedema 
cause swelling and damage to the tissue at the site of infection.    
 
 Pharmacokinetics (PK), “what the body does to the drug”, describes the fate of a drug 
as the host handles it through the mechanisms of absorption, distribution, metabolism 
and elimination (ADME).  Based on the route of administration, this will result in 
specific drug concentration over time in the bloodstream (systemic exposure), the 
dermal interstitial fluid of the infected skin (the target site) and other parts of the body 
(off-target). Mathematical models can describe the behaviour of the drug in the blood 
(the central compartment) and the tissues (the peripheral compartment). Adequate 
drug exposure at the site of infection in terms of both concentration and time course 
are essential for an antimicrobial to exert its activity (136). Achieving the right 
therapeutic drug exposure is a delicate balance: sub-therapeutic exposure could lead 
to a lack of efficacy or the emergence of resistant parasite populations, supra-
therapeutic drug levels can lead to toxicity and off-target effects.  Table 2 lists the 
most important PK parameters. 
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Table 2: Overview of fundamental PK parameters 
 
Parameter Symbol Description  Unit (example) Formula 
Dose D the dose of drug administered Mg Design 
parameter 
Dose interval   τ once per day (QD) 
twice per day (BD)  
trice per day (TID) 
Per hour, per 
day 
Design 
parameter 
Cmax Cmax the maximal concentration in a 
specific matrix (usually in plasma, but 
can be in any part of the body) after 
drug administration 
µg/ml Direct 
measurement 
Tmax Tmax the time corresponding to Cmax Hours Direct 
measurement 
Volume of 
distribution 
Vd the apparent volume in which a drug 
is distributed. Relates drug 
concentration to the amount of drug 
in the body and can give information 
about tissue distribution 
Litre  =D/C0 
Elimination rate 
constant 
Ke the rate at which a drug is removed 
from the system  
Per hour = Cl/VD  
= ln(2)/T1/2 
Clearance Cl the volume of body fluid cleared per 
time unit quantifies drug elimination 
from the system by kidney, liver and 
other organs 
litre/hour = Vd.Ke 
=D/AUC 
Half-life T1/2 the time needed for the 
concentration to fall to half of its 
previous value 
Hours = ln(2)/Ke 
AUC AUC the area under the curve, an 
expression of total exposure 
mg/liter.hour =[∫ C. 𝑑𝑡
∞
0
]  
 
Bioavailability F oral bioavailability, the fraction of the 
administered dose that reaches the 
systemic circulation. 
N/A 
(fraction) 
=AUC(po)/ AUC(IV) 
x Dose(IV)/Dose(po) 
 
Some important concepts for the PK of CL drugs include: 
o The target site for drug action is the dermis underneath the skin lesion, where 
parasites survive and multiply as intracellular amastigotes in the phagolysosomes 
of (predominantly) macrophages. Hence, plasma and even extracellular dermal 
fluid might not be a good surrogate for the intracellular concentrations to which 
the pathogen is exposed, based on the ability of a systemic drug to extravasate at 
the infection site or the tendency of the drug to predominantly distribute extra- 
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or intracellularly (136). The acidic environment of the phagolysosome (pH=4-5) 
and several biological membranes could form biological barriers for a drug on its 
cellular route towards its molecular target (137). The effect of manipulation of the 
low pH of the phagolysosome with alkaline lysosomotropic drugs such as 
chloroquine (CQ) on parasite survival has not yet been explored. Therefore, we 
studied the in vitro and in vivo antileishmanial effects of standard drugs alone or 
in combination with CQ in chapter 3.1.   
o Not only the physicochemical properties but also the route of administration 
influences the PK route of a drug. For example, an oral compound requires 
sufficient uptake through the intestinal epithelia to reach the bloodstream 
(bioavailability), limited first-pass metabolism (unless it is a prodrug) and 
distribution from the systemic circulation to the skin. A successful topical drug, on 
the other hand, needs the ability to permeate through the stratum corneum of the 
epidermis and to be retained in the dermis (139). Local, disease-inflicted tissue 
damage and pathophysiological alterations might affect local drug accumulation, 
but this has not been studied for most antileishmanial drugs. Local acidosis of the 
extracellular fluid due to inflammation, low oxygen tension and altered local blood 
flow, capillary density, capillary permeability and lymphatic clearance could all 
affect the fate of a drug within CL skin lesions (136). However, the significance of 
these phenomena for the pharmacology of CL drugs is poorly understood.   
o Once drug penetration into the skin has occurred, drug disposition within the 
infected tissue is unlikely to be a uniform, rapid or complete process. Little is 
known about drug penetration in the non-caseating granuloma in which infected 
macrophages are organized (140), drug uptake by off-target cells, or binding of 
drugs to extracellular biological material in the skin. 
o Only the unbound drug concentration, free of protein binding, surrounding the 
therapeutic target is pharmacologically active and can lead to in vivo efficacy by 
binding to and acting on its molecular target. At the same time, compounds with 
low protein binding are cleared from the system to a greater extent and can have 
a shorter plasma half-life (141).  
o A drug can be both inactivated and activated by the metabolism of the parasite or 
the host (in macrophages, skin and liver). Leishmania-specific enzymes, such as 
type I nitroreductases, could be exploited for the activation of prodrugs within the 
parasite (142).  
o Different types of CL require variable PK profiles for drug efficacy, for example, 
local accumulation within a single simple CL lesion versus high systemic exposure 
and distribution to all skin sites for DCL and PKDL. Moreover, drug exposure could 
vary in specific populations such as children or immunosuppressed patients.     
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 Pharmacodynamics (PD), “what the drug does to the body”, describe how the drug 
affects the parasite that causes infection and pathology to the host. Drug 
concentrations at specific sites of the body can result in the desired antileishmanial 
(target) as well as undesired toxic (off-target) effects. Indeed, selective drug 
distribution and toxicity to target the pathogen rather than the host is the basis of the  
“magic bullet” concept coined by Paul Ehrlich, the father of anti-infective 
chemotherapy (143). Binding of protein-free drug to its molecular target for a specific 
duration of time is the pharmacological basis for antileishmanial activity. PD can be 
described in terms of activity (inhibitory concentrations, such as EC50, EC90), potency 
(maximal effect) and rate of kill (time-dependence of the effect) (144). Some 
important PD concepts for CL drugs include:  
 
o Leishmania species show a significant variation in their sensitivity to standard 
(SbV, PM, MF) and experimental drugs, as observed in vitro, in vivo and during 
clinical trials (145, 146).  
o Recent research has shown that Leishmania can have metabolically semi-
dormant and actively replicating states in vivo. Latency is a well-characterized 
phenomenon for other pathogens such as Mycobacterium tuberculosis. Hence, 
drug activity against parasite subpopulations with different growth rates 
might be variable, leading to persisting parasites and the risk of treatment 
failure and relapse (147-149).  
o Therapeutic efficacy of a drug against CL is a combination of its leishmanicidal 
activity and the protective role of the immune system. Particularly important 
to therapy are macrophages, the Leishmania host cells. These are 
heterogeneous cell populations, with variable phenotypes based on their 
resident tissue microenvironment (150), activation status (5) and host-
pathogen interaction (16). Therefore, it is important to understand the role of 
drug accumulation (uptake and efflux transporters, metabolism) within 
infected macrophages, as well as their own independent antileishmanial 
activity upon activation (138). In vitro activity of standard antileishmanial drugs 
has already been shown to be dependent on the type of the macrophage host 
cell (150).    
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1.5.5. Current drug development tools for CL  
 
The current predictive models and tools to evaluate antileishmanial activity can be classified 
into in vitro and in vivo tests. Figure 18 shows the most important models in CL drug research.  
 
 
Figure 18: In vitro and in vivo models of CL – Leishmania-infected macrophages (nuclei: N, 
intracellular amastigotes, A and arrows) and BALB/c mice with skin lesions on the rump (L) 
 
 In vitro phenotypic screening assays evaluate activity and potency of the drug against 
Leishmania. These can be categorized as promastigote, axenic (extracellular) 
amastigote and intracellular amastigote assays. Extracellular models (promastigote 
and axenic amastigote) allow for higher-throughput, cheaper, quicker and more 
straightforward screening. However, they do not reflect the biological complexity of 
CL in humans (parasites reside within the macrophages of the dermal skin layer) and 
can thus lead to false positives and negatives. The intracellular amastigote model 
(infected macrophages) is the gold standard. Macrophages can be derived from 
mouse peritoneum (PEMs) or bone-marrow (BMM), or chemically differentiated from 
human cancer cell lines (THP-1). Infected macrophages are exposed to specific drug 
concentrations for a standardised period (such as 2, 3 or 5 days), after which cells are 
fixed with methanol and stained with Giemsa dye before microscopic counting of the 
number of amastigotes per host cell (parasite burden) or the percentage of host cells 
containing at least one amastigote (% infection). Back-transformation assays, in which 
viable amastigotes return to their promastigote life-stage in culture, can be used to 
confirm findings. Alternatively, Leishmania-specific enzymatic, colourimetric or 
fluorometric reactions allow higher throughput, automated and more rapid screening. 
New compounds can be selected based on the 50 % and 90 % effective concentrations 
(EC50, EC90) after comparison with an untreated control and a control drug. 
Macrophage viability (Alamar Blue, Lactate Dehydrogenase) and general cytotoxicity 
assays (HEPG2 assays) should accompany activity screening assays to ensure selective 
toxicity towards the parasites rather than the mammalian host cells (151, 152). The 
use of different macrophage cell lines (which can affect antileishmanial activity (150)) 
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and the broad range of exposure times make a comparison of available scientific data 
challenging. Harmonisation of Leishmania drug research procedures is urgently 
required.    
 
A major issue with these in vitro models is their lack of biological relevance, as they 
are static and two-dimensional culture systems: drug activity is evaluated at a single 
time point after exposure of cells adhered to a surface of a culture well slide to a single 
drug concentration.  Yet, in vivo, efficacy is a dynamic process of rate and magnitude 
of parasite kill as a result of fluctuating drug levels surrounding infected dermal 
macrophages, with or without the assistance of the host immune response. The 
oversimplification can cause a poor in vitro – in vivo correlation. 3D cell culture and 
flow systems help to bridge the gap between in vitro models and live tissue during 
drug discovery (153, 154). 
 
In this simple in vitro model, the only biological barriers in terms of PK a drug needs 
to pass in order to exert its antileishmanial activity are cellular (macrophage, 
phagolysosome, parasite). In silico modelling based on physicochemical drug 
properties and physiological determinants are used to predict the PK profile of new 
compounds (155). General in vitro ADME assays (MDCKII-hMDR1 cell permeability, 
CYP450 interactions, metabolic stability in liver and skin) can provide a more robust 
evaluation and improve the likelihood of success for lead candidates (156).     
 
 In vivo models of CL for the evaluation drug efficacy are mainly mouse-based. A 
standardized inoculum of virulent Leishmania promastigotes is injected intradermally 
or subcutaneously in the footpad, rump or ear of a mouse. L. major-BALB/c is the most 
common and best-studied animal model of CL. The major advantages are its high 
reproducibility, robustness and relatively rapid development of skin lesions (typically 
within 2-4 weeks). Because the susceptible BALB/c mouse is immunologically 
incapable of self-curing L. major infection, the model forms a rigorous drug evaluation 
test as only potent compounds show efficacy. Because humans do often self-cure CL, 
this lack of clinical relevance is also the main limitation of the model. Alternative 
rodent models of CL, such as C57/bl6 mice or golden hamsters do show self-cure 
profiles, but disease onset is typically much slower, resulting in lower throughput and 
higher maintenance costs. In vivo drug efficacy in animal models of CL is determined 
in terms of reduction of lesion size compared to an untreated control. However, 
because inflammation is an important factor in lesion size and thus a potential 
confounding factor for drug activity, quantification of Leishmania parasite load should 
be considered as another indicator of therapeutic effect. This can be done via limiting 
dilution assays, quantitative polymerase chain reaction (qPCR), microscopy, ELISA, or 
in vivo imaging of bioluminescent parasites. Based on dose-response studies, the 50% 
and 90 % effective dose (ED50 and ED90) can be calculated. The therapeutic index 
describes the window between the desired therapeutic and undesired toxic/lethal 
effects of the drug (ED50/LD50). In vivo toxicity measures can be death, weight loss or 
behavioural abnormalities in animals (157, 158). 
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Alongside activity and toxicity data, PK information should also be collected, as the 
ability of the drug to permeate biological barriers and reach the infected dermal 
macrophages is crucial for therapeutic efficacy. However, skin PK research in animal 
models of CL is a poorly explored area (159-161), while some work has been done in 
recent years for VL (162-166). An issue for skin PK studies is the cost related to the 
required number of animals. While tail vein sampling in mice makes plasma drug levels 
easy to obtain, these are poor surrogate markers for drug exposure at the actual 
infection site in the skin. Tissue homogenates from skin necropsies or skin biopsies are 
straightforward to perform and give a crude PK measure of drug distribution in lesions. 
However, grinding up tissues results in combined drug levels from various skin 
compartments that can be difficult to interpret. For intracellularly accumulating drugs, 
such as quinolones and macrolides (AmB), this can lead to a relative dilution and 
underestimation of the exposure within the amastigote-containing macrophages. 
Alternatively, this approach might overestimate intracellular levels of drugs with a 
preferential distribution in the extracellular compartments, such as such as β-lactams 
and aminoglycosides (PM) (137, 167). The strengths and limitations of skin 
homogenates are discussed further in chapters 3.1, 3.2, 3.3 and 3.4. A more 
appropriate method for the study of the penetration of anti-infective drugs in tissues 
is microdialysis (MD). This minimally invasive technique allows real-time sampling of 
unbound drug concentrations but requires technical skill and a more complex, 
expensive experimental set-up (168, 169). This method is described in detail in chapter 
3.5.     
 
Combining in vitro and in vivo assays, figure 19 shows an example of an algorithm for selecting 
new oral drug candidates for CL. The cascade follows specific tests to evaluate the drug’s 
antileishmanial efficacy, toxicity, metabolism and PK (in order of increasing biological 
relevance, but also costs, time and workload) and provides go/no-go criteria for the selection 
of the most promising compounds along the way (170).   
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Figure 19: an oral drug discovery scheme for CL. MTA = material transfer agreement. T.I = 
therapeutic index. HepG2 = human liver cell line (preclinical toxicity assay). 
 I.p. = intraperitoneal. MLS = mouse leishmaniasis suppression. ID = identification. MLL = mouse 
leishmaniasis lesion. P.o. = per os (oral). PK = pharmacokinetics. IVMN = in vitro micronucleus assay ( 
preclinical genotoxicity assay). hERG = human ether-a-go-go-related gene (preclinical cardiotoxicity 
assay). Ames testing (preclinical carcinogenicity assay). DDI = drug-drug interaction. SAR  = structure 
activity relationship.  
 
 
However, high failure rates in the clinic remind us to be cautious when interpreting activity, 
safety or ADME results from preclinical models of disease. Our predictive models for CL R&D 
might not represent the pathogenicity, virulence, diversity and susceptibility of the parasites 
or the behaviour of the drug in clinical situations. This may lead to decisions to advance the 
wrong compounds through drug discovery programmes, ending up with an enormous loss of 
time and resources rather than a new treatment. So how can we translate data from 
preclinical to clinical trials? How do we bridge the gaps between cellular/animal models of 
infection and human disease? An important strategy to overcome such issues is a better 
understanding of PK/PD relationships.  
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1.5.6. PK and PK/PD in CL drug development   
 
Antimicrobial activity of an antibiotic is classically defined in terms of inhibitory 
concentrations, such as minimally inhibitory concentration (MIC) and 90 % effective 
concentration (EC90). These values, however, do not give information about the time-
dependency of the antimicrobial effect. By incorporating PD potency measures with PK data, 
it is possible to identify the most important parameters for antimicrobial effect by 
understanding the relationship between PK and PD (PK/PD). Based on the PK/PD profile, drugs 
can be classified in roughly three groups: concentration-dependent, time-dependent or 
dependent on both time and concentration. For example, for aminoglycosides such as PM, 
the maximum plasma concentration (Cmax/MIC) is most important for its antibacterial effect 
(concentration-dependence). For antibiotic classes such as β-lactams, the period that plasma 
concentrations are above the MIC (T>MIC) is the crucial determinant of activity (time-
dependence) (171, 172). Figure 20 gives an overview of these basic concepts and parameters 
in PK/PD. By integrating PK and PD information derived from preclinical in vitro and in vivo 
studies, translational drug research and PK/PD modelling can predict human dose regimens 
with clinical efficacy. Various mechanism-based and empirical PK/PD mathematical modelling 
approaches exist to describe the exposure-response relationship (173 - 175), but details are 
beyond the scope of this thesis. 
 
 
Figure 20: Overview of the basic concepts of PK/PD modelling (171) 
 
In recent years, analysis of PK/PD relationships has become central to drug development. A 
team from Pfizer analysed the role of fundamental PK/PD in the survival rate of compounds 
in clinical trials (176). The majority of failures were caused by a lack of efficacy during Phase 
II. They defined the “three pillars of survival” for a new drug candidate as (i) exposure at the 
target site of action over a desired period of time (ii) binding to the pharmacological target as 
expected for its mode of action and (iii) expression of pharmacological activity as expected 
for the demonstrated target exposure and target binding. These are concepts directly related 
to fundamental pharmacology and PK/PD. The Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) have not only endorsed PK/PD as a valuable approach to 
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optimize and streamline drug development, today it is a critical requirement for licensing a 
new medicine (177, 178).  
Translational PK/PD modelling can minimize the risk of failure and shorten the time and cost 
of drug development for new antimicrobial drugs (179-181). Indeed, an analysis of 19 
antibacterial drug approval decisions from 1996 to 2011 showed that as the probability of 
PK/PD target attainment for a given dosing regimen increased, so did the chance of regulatory 
approval (182). PK/PD plays a critical role in establishing safe and effective combination 
therapies for major tropical diseases such as malaria (183) and tuberculosis (184).  
For leishmaniasis, researchers have only very recently begun to investigate the PK, PD and 
PK/PD of standard antileishmanial drugs (AmB, MF) in preclinical models of VL, to serve as a 
model for the evaluation of new drug candidates (166, 185). In addition, the PK and PD 
properties of current drugs in leishmaniasis pharmacotherapy are poorly understood. As a 
result, treatment regimens are empirical and based on the maximum tolerated doses, rather 
than rationally designed and optimized. This leaves patients at risk of drug-related adverse 
and toxic effects, therapeutic failure and relapse after initial cure (62).    
Thus, the PK/PD concept holds untapped potential to support in the delivery of new and 
better treatments for CL. Drug development for CL is scientifically challenging, due to (i) the 
dermal site of infection, (ii) the intracellular location of the causative parasite within 
macrophages and (iii) the variability in drug sensitivity among Leishmania species. At the same 
time, there is a lack of rational approaches to accelerate successful drug R&D for this 
disfiguring disease. By combining aspects of infection site PK and Leishmania kill kinetics, 
PK/PD analysis is able to quantitatively describe and simulate the complex interaction 
between antileishmanial drug, parasite and patient. However, before the role of PK/PD can 
be explored in CL treatment, improved tools are needed to evaluate the PK and PD properties 
of established and new antileishmanial drugs.  
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2. AIMS AND OBJECTIVES 
 
The aim of this thesis is to develop new tools to support the preclinical development of much 
needed novel drugs for cutaneous leishmaniasis (CL). Such tools include predictive models, 
methodologies and strategies to evaluate the therapeutic efficacy of new compounds based 
on assessing favorability of their skin pharmacokinetics (PK), antileishmanial 
pharmacodynamics (PD) and pharmacokinetic/pharmacodynamic (PK/PD) relationships. 
These were established and validated using standard antileishmanial drugs such as 
amphotericin B, miltefosine and paromomycin (chapter 3.1, 3.2, 3.3 and 3.4) and then applied 
to a new clinical drug candidate for leishmaniasis (chapter 3.5), as detailed below.   
 
 In chapter 3.1, we investigated the potential of combination therapy of standard 
antileishmanial drugs with the 4-aminoquinoline as a new treatment strategy for CL. 
The chapter discusses the challenges of in vitro-in vivo translation and species-specific 
drug sensitivity in CL drug discovery.   
 
 In chapters 3.2 and 3.3, we compared PK and efficacy of different formulations of the 
2nd-line drug AmB (Fungizone® (deoxycholate), AmBisome® (unilamellar liposome) 
and Fungisome® (multilamellar liposome)) in a mouse model of L. major CL. The aim 
was to learn lessons for liposomal drug delivery to the CL target site and to provide a 
basis for rational design of clinical drug dose regimens.   
 
 In chapter 3.4, we studied the influence of local skin inflammation in L. major and L. 
mexicana CL of the PK and PK/PD of AmBisome®. The aim was to identify whether the 
influence of pathophysiology on PK could be a contributing factor in variable 
treatment outcomes in Old and New World CL.   
 
 In chapter 3.5, we evaluated the PK and efficacy of DNDI-0690, an oral nitroimidazole 
and clinical candidate for VL, in preclinical models of CL. The aim was to characterize 
drug distribution in the infected skin (using an innovative microdialysis method) and 
study the dose-response effect in the L. major BALB/c model of CL.  
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3. EXPERIMENTAL RESULTS  
 
The results of this project will be shown in the following pages as four chapters in the form of 
research papers (chapters 3.1, 3.2, 3.3 and 3.4) and one book style chapter (chapter 3.5).  
 
The four publications arising from this PhD project are:  
3.1. Wijnant G-J, Van  Bocxlaer K, Yardley V, Murdan S, Croft SL. 2017. Efficacy of 
Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous 
Leishmaniasis. Antimicrob Agents Chemother 61. 
 
3.2. Wijnant G-J, Van Bocxlaer K, Yardley V, Harris A, Murdan S, Croft SL. 2018. Relation 
between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine 
Cutaneous Leishmaniasis. Antimicrob Agents Chemother 62. 
 
3.3. Wijnant, G.-J., Van Bocxlaer, K., Yardley, V., Harris, A., Alavijeh, M., Silva-Pedrosa, 
R., Antunes, S., Mauricio, I., Murdan, S., and Croft, S.L. 2018. Comparative efficacy, 
toxicity and biodistribution of the liposomal amphotericin B formulations 
Fungisome® and AmBisome® in murine cutaneous leishmaniasis. International 
Journal for Parasitology: Drugs and Drug Resistance.  
 
3.4. Wijnant, G.-J., Van Bocxlaer, K., Francisco, A.F., Yardley, V., Harris, A., Alavijeh, M., 
I., Murdan, S., and Croft, S.L. 2018. Local skin inflammation in cutaneous 
leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of 
liposomal amphotericin B. Manuscript under review for publication by 
Antimicrobial Agents and Chemotherapy – minor corrections.  
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Chapter 3.1:  
 
Combination therapies of 
chloroquine with standard 
antileishmanial drugs for CL 
treatment 
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3. 1: Combination therapies with chloroquine for CL treatment 
 
ANNEX 1: WIJNANT G-J, VAN BOCXLAER K, YARDLEY V, MURDAN S, CROFT SL. 2017. 
EFFICACY OF PAROMOMYCIN-CHLOROQUINE COMBINATION THERAPY IN 
EXPERIMENTAL CUTANEOUS LEISHMANIASIS. ANTIMICROB AGENTS CHEMOTHER 
61. 
 
  
Key points, novel results and implications 
 This work was started in July 2015 to allow basic training for in vitro (cell culture, 
molecular biology) and in vivo (animal handling, infection, drugging) methods for the 
rest of the project (chapter 3.2, 3.3, 3.4 and 3.5).   
 The 4-aminoquinoline chloroquine (CQ) is a safe, oral antimalarial medication. In 
addition, the drug is also clinically used in combination with doxycycline to cure 
chronic Q fever, as it enhances the activity of the antibiotic against the causative 
bacterium Coxiella burnetii. The mechanism for therapeutic synergy between 
doxycycline and CQ is related to CQ-mediated manipulation of the pH of the 
macrophage phagolysosomes where C. burnetii multiplies. As Leishmania parasites 
occupy a similar intracellular site within the host, it was hypothesized that a similar 
drug combination approach might be the basis for a new, improved treatment for CL.  
 Of the three standard drugs (miltefosine, amphotericin B, paromomycin) evaluated in 
vitro in combination with CQ in 72-hour intracellular drug assays, we identified 
significant increases in antileishmanial activity for paromomycin (PM). 
 The PM-CQ drug combination was then tested in murine models of L. major and L. 
mexicana CL. Daily co-administration of 50 mg/kg PM and 25 mg/kg CQ (IP) for 10 days 
resulted in a significant reduction in lesion size but not in parasite load compared to 
those found for controls which received PM alone.   
 Overall, our data indicate that a drug combination of PM and CQ is unlikely to be a 
potential candidate for further preclinical development for CL. The paper discusses 
the current preclinical drug development scenario for CL and its limitations, with 
special attention for the challenging translation from in vitro to in vivo. 
 In the frame of the thesis, this chapter identified (i) in vitro activities for standard drugs 
against the two main Leishmania strains used in this work (Old World L. major JISH118 
and New World L. mexicana M379) and confirmed species-specific differences in 
antileishmanial drug sensitivity. Furthermore, the paromomycin dose regimen (10 x 
50 mg/kg, IP) served as a strong positive control for in vivo activity against L. major in 
later studies (chapter 3.3 and chapter 3.4).  
 
Candidate’s contribution  
The candidate generated and analysed all the data described in the paper. Moreover, he 
prepared the first draft of the manuscript, which was accepted for publication by 
Antimicrobial Agents and Chemotherapy in May 2017 after academic peer review.  
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3.2: AmBisome treatment of CL - relation between skin PK and efficacy 
 
ANNEX 2: WIJNANT G-J, VAN BOCXLAER K, YARDLEY V, HARRIS A, MURDAN S, 
CROFT SL. 2018. RELATION BETWEEN SKIN PHARMACOKINETICS AND EFFICACY IN 
AMBISOME TREATMENT OF MURINE CUTANEOUS LEISHMANIASIS. ANTIMICROB 
AGENTS CHEMOTHER 62. 
 
Key points, novel results and implications 
 One of the main aims of this thesis was to develop methodologies to investigate the 
PK, PD and PK/PD properties of new drug candidates for the treatment of CL. To first 
validate such an approach and related methods, we used the standard drug 
amphotericin B (AmB) in the unilamellar liposomal formulation AmBisome (LAmB). 
The choice for AmBisome as a standard drug was justified by: 
o The availability of earlier reports on its excellent efficacy in the L. major –
BALB/c mouse model of CL. 
o The large body of scientific literature on its PK and PK/PD properties because 
of its important role in the treatment of systemic fungal infections.  
o The experience of our industrial partner Pharmidex for the quantification of 
AmB in biological matrices by LC-MS/MS.  
 
 LAmB is a standard 2nd-line drug in the treatment of (M)CL. However, very little is 
known about skin distribution and PD to inform clinical use.  
 We compared the skin PK of LAmB with those of the deoxycholate form of AmB 
(DAmB; trade name Fungizone) in a murine model of L. major CL.  After administration 
of 5 doses at 1 mg/kg (IV) over 10 days, AmB levels at the target site (the localized 
lesion) were 3-fold higher for LAmB than for DAmB. For both formulations, drug 
concentrations in lesions were 20-fold higher than those in the healthy control skin of 
the same infected mice. Skin PK was based on necropsy and tissue homogenisation.  
 We then evaluated how drug levels in the lesion after higher-dosed LAmB treatment 
(1 mg/kg = acute toxicity limit for DAmB) relate to therapeutic outcomes on day 10. A 
clear-dose response up to 12.5 mg/kg was found after LAmB administration at day 0, 
2, 4, 6, and 8 and there was a clear correlation between dose, intralesional AmB 
concentration, and relative reduction in parasite load and lesion size (R2 > 0.9).  
 Overall, we present the first PK/PD-based investigation of LAmB in CL, which can form 
a basis for the development of optimized clinical dose regimens in patients. 
Furthermore, the data indicates encapsulation of antileishmanial drugs in liposomes 
could be a suitable strategy for targeted delivery in CL drug development.   
 In the frame of the thesis, we confirmed the dose- and skin concentration-dependent 
in vivo activity of intravenous LAmB in murine CL. The PK/PD-based approach to drug 
evaluation provided a framework to provide a head-to-head comparison of different 
compounds and (liposomal) formulations, as done in chapter 3.3. Moreover, we 
hypothesised that it was the local inflammation in the diseased skin tissue that 
enhanced drug accumulation in lesions, which was investigated in chapter 3.4.  
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The candidate generated and analyzed all data described in the paper, except for LC/MS-MS 
quantification of drug levels in samples and calculation of PK parameters with WinNonLin 
software (Pharmidex Pharmaceutical Services Ltd.). The candidate prepared the first draft of 
the manuscript, which was accepted for publication by Antimicrobial Agents and 
Chemotherapy in December 2017 following academic peer review.  
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3.3: AmBisome treatment of CL – comparison with Fungisome    
 
 
ANNEX 3: WIJNANT, G.-J., VAN BOCXLAER, K., YARDLEY, V., HARRIS, A., ALAVIJEH, 
M., SILVA-PEDROSA, R., ANTUNES, S., MAURICIO, I., MURDAN, S., AND CROFT, S.L. 
2018 COMPARATIVE EFFICACY, TOXICITY AND BIODISTRIBUTION OF THE 
LIPOSOMAL AMPHOTERICIN B FORMULATIONS FUNGISOME® AND AMBISOME® IN 
MURINE CUTANEOUS LEISHMANIASIS. INTERNATIONAL JOURNAL FOR 
PARASITOLOGY: DRUGS AND DRUG RESISTANCE.  
 
Key points, novel results and implications 
 After investigating skin PK and antileishmanial PD of AmBisome in murine CL 
(chapter 3.2), we wanted to further study the influence of liposomal drug formulation 
on biodistribution and efficacy. To do this, we compared AmBisome with Fungisome, 
an alternative liposomal AmB product called Fungisome which is used in India in VL 
and PKDL treatment. However, it has not yet been tested against CL.  
 Here, we report a head-to-head comparison of Fungisome with AmBisome in terms 
of efficacy, toxicity and skin distribution in the L. major BALB/c mouse model of CL. 
 Upon intravenous administration at dose levels of 5, 10 and 15 mg/kg of body weight 
(on days 0, 2, 4, 6 and 8), Fungisome showed clear signs of toxicity (at 15 mg/kg), while 
AmBisome did not. After complete treatment (day 10), the tolerated doses of 5 and 
10 mg/kg Fungisome had significant antileishmanial activity (ED50=4.0 and ED90 =12.8 
mg/kg for qPCR-based parasite load and lesion size, respectively), although less than 
that of AmBisome at identical doses (ED50 =3.0 and ED90 =8.8 mg/kg). The efficacy of 
Fungisome was inferior compared to AmBisome because lower levels of the active 
agent AmB accumulated within the infected lesion.  
 Differences in a number of physicochemical and pharmacokinetic parameters 
between the two liposomal formulations, which could explain the variable toxicity and 
efficacy of AmBisome and Fungisome, are discussed in depth in the paper. 
 In conclusion, despite possibly being less safe and efficacious than AmBisome at 
equivalent doses, the moderate in vivo activity of Fungisome could indicate a minor 
role in the systemic pharmacotherapy of CL and PKDL. Moreover, in CL drug 
development, encapsulation of drugs in AmBisome-like compared to Fungisome-like 
liposomes could lead to lower toxicity and higher skin accumulation and thus efficacy.  
 A new reverse transcriptase qPCR method to measure skin parasite load based on 
Leishmania RNA (rather than DNA) was developed with the help of colleagues at the 
Institute of Hygiene and Tropical Medicine of Lisbon, Lisbon. For a direct comparison 
between DNA- and RNA- based parasite load results, please see the supplementary 
material.    
 In the frame of this thesis, we used the PK/PD-based approach to demonstrate the 
higher efficacy of AmBisome compared to Fungisome is directly related to increased 
drug accumulation at the infection site. A similar strategy was then applied in chapter 
3.5. to compare a new drug candidate, DNDI-0690 with the standard antileishmanial 
drug paromomycin (chapter 3.1). 
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Candidate’s contribution 
The candidate generated and analyzed all data described in the paper, except for LC/MS-MS 
analysis of drug concentrations in the samples (Pharmidex Pharmaceutical Services Ltd.). As 
part of the Euroleish Network requirements for mobility of Marie-Curie fellows, the candidate 
spent time at the Institute of Hygiene and Tropical Medicine in Lisbon, Portugal, to develop a 
new RT qPCR method for quantification of parasite load. The candidate prepared the first 
draft of the manuscript, which was accepted for publication by International Journal of 
Parasitology: Drugs and Drug Resistance in April 2018 following academic peer review.  
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3.4: Local skin inflammation in CL as a source of variable PK and efficacy of AmBisome®     
   
ANNEX 4: WIJNANT, G.-J., VAN BOCXLAER, K., FRANCISCO, A.F., YARDLEY, V., 
HARRIS, A., ALAVIJEH, M., I., MURDAN, S. , AND CROFT, S.L. 2018. LOCAL SKIN 
INFLAMMATION IN CUTANEOUS LEISHMANIASIS AS A SOURCE OF VARIABLE 
PHARMACOKINETICS AND THERAPEUTIC EFFICACY OF LIPOSOMAL AMPHOTERICIN 
B. UNDER REVIEW FOR PUBLICATION BY ANTIMICROBIAL AGENTS AND 
CHEMOTHERAPY.  
 
Key points, novel results and implications 
 In chapter 3.1, we showed that there were differences in vivo drug susceptibilities 
between L. major and L. mexicana. In chapter 3.2, we demonstrated that drug 
accumulation after AmBisome treatment was significantly higher in the Leishmania-
infected skin than in the healthy, uninfected counterparts. We hypothesized that this 
was due to local tissue inflammation, which could lead to increased vascular 
permeability and macrophage recruitment at the infection site.  These 
pathophysiological parameters could cause variable pharmacokinetics of AmBisome. 
Additionally, the degree of skin inflammation could vary between disease stages and 
causative parasite species.   
 In this chapter, we have investigated the impact of local skin inflammation on the PK 
and efficacy of AmBisome in two murine models of localized CL (Leishmania major 
and Leishmania mexicana) at three different stages of disease (papule, initial nodule 
and established nodule). 
 Twenty-four hours after administration of 1 x 25 mg/kg AmBisome (IV) to CL-infected 
BALB/c mice, drug accumulation in the skin was found to be dependent on the 
causative parasite species (L. major > L. mexicana) and the CL disease stage (papule > 
initial nodule > established nodule > healthy skin). Elevated tissue drug levels were 
associated with increased vascular permeability (Evans Blue assay) and macrophage 
infiltration (histomorphometry) in the infected skin, two pathophysiological 
parameters linked to tissue inflammation. After identical treatment of CL in the two 
models with 5 x 25 mg/kg AmBisome (IV), intralesional drug concentrations and 
reductions in lesion size and parasite load (qPCR) were all ≥ 2-fold higher for L. major 
compared to L. mexicana. 
 In conclusion, the superior therapeutic efficacy of LAmB against L. major compared to 
L. mexicana could be explained in part by improved drug accumulation at the infection 
site, due to the presence of a more severe local skin inflammation.  
 Overall, our data indicate that there might be a need for specific AmBisome treatment 
guidelines for CL caused by L. major in the Middle-East and L. mexicana in Latin-
America. This is the first time that inflammation and histopathology are linked to PK 
in CL treatment, which is an important consideration in the development of preclinical 
drugs and clinical dose regimens.  
 We developed a new model of local skin inflammation (the so-called ‘pseudolesion’), 
and methods to quantify the number of inflammatory cells and macrophages in skin 
lesions. Moreover, we confirmed the presence of increased blood vessel leakiness, an 
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important parameter in the tissue distribution of systemic drugs, for the first time in 
experimental CL using the Evans Blue Assay.      
 In the frame of the thesis, this chapter helped to understand the underlying 
pathophysiological mechanisms that could explain the differences in drug 
accumulation we have observed in the diseased and the healthy skin in murine CL in 
chapter 3.2, 3.3 and 3.5. 
 
 
Candidate’s contribution 
The candidate generated and analyzed all data described in the paper, except for LC/MS-MS 
quantification of drug levels (Pharmidex Pharmaceutical Services Ltd.), histological staining 
(UCL Institute of Neurology) and histomorphometry (Amanda Fortes Francisco, LSHTM). The 
candidate prepared the first draft of the manuscript, which was accepted for publication in 
Antimicrobial Agents and Chemotherapy in July 2018. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
81 
 
Research paper cover sheet  
  
Copyright proof 
 
 
   
 
82 
 
Research paper  
 
 
(double-click to open attached file) 
 
   
 
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
98 
 
Chapter 3.5: 
 
PK and PK/PD-based efficacy evaluation 
of the drug candidate DNDI-0690 for 
the treatment of CL  
 
 
   
 
99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
100 
 
3.5: PK and PK/PD-based efficacy evaluation of the drug candidate DNDI-0690 for the 
treatment of CL  
 
3.5.1. Introduction 
 
DNDI-0690 (figure 21) is a New Chemical Entity (NCE) developed by the non-profit public-
private partnership Drugs for Neglected Diseases Initiative (DNDI) for the treatment of VL 
(132). Chemically, the compound is a 7-substituted nitroimidazooxazine belonging to the 
nitroimidazole class, a medically important group of nitro-based antimicrobial drugs with a 
broad spectrum of activity against parasites, mycobacteria, gram-positive and gram-negative 
bacteria. Examples of important nitro-based antibiotics are metronidazole (amoebiasis, 
giardiasis, trichomoniasis) nifurtimox (sleeping sickness), benznidazole (Chagas disease) and 
delamanid (tuberculosis). Nitroimidazoles are prodrugs: the nitro group is crucial to the 
antimicrobial model of action, as it is reduced to reactive radical species that react with 
cellular components such as proteins and DNA within the pathogen (186). Indeed, 
Leishmania-specific nitroreductases have already been shown to be responsible for bio-action 
of nitro-compounds (142). While nitroimidazoles were discovered in the 1950s, there has 
recently been a renewed interest in this drug class for the treatment of various (neglected) 
tropical diseases.  
Originally identified in a library of potential antitubercular drugs, DNDI-0690 was nominated 
by DNDI in 2015 as a preclinical candidate after showing excellent in vitro activity against a 
panel of VL and CL Leishmania strains. In 2016, activities focussed on pharmaceutical 
development (synthesis, manufacture, product development). In 2017, a full preclinical 
toxicology and safety study package was completed. In 2018, the decision was made to 
conduct Phase I clinical trials in healthy volunteers to assess safety, tolerability and 
pharmacokinetics in microdosing studies. In terms of PK, the drug candidate has a relatively 
short plasma half-life (~ 7 hours) and high protein binding (~ 95%). Based on PK and  PD mouse 
and hamster data, the predicted dose range for efficacy against human VL has been calculated 
between 19 and 52 mg/kg twice daily via the oral route. However, for CL, there is limited PK, 
PK/PD and efficacy data in animal models available. Such information is required to support 
further development of the drug candidate into a new oral medication for the treatment of 
CL (187, 188).  
 
Figure 21: Chemical structure of the nitroimidazole compound DNDI-0690 
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3.5.2. Physicochemical properties of DNDI-0690 
  
We estimated the physicochemical properties of DNDI-0690 using Chem3D 16.0 software 
(189). Figure 22 shows the predicted 3D structure of DNDI-0690.  
 
Figure 22:  Predicted 3D structure of DNDI-0690 (Chem3D 16.0) 
 
Lipinski’s rule of five states that most orally active drugs in humans share particular 
physicochemical properties, such as low molecular weight (< 500 Da) and moderate 
lipophilicity while retaining a decent degree of aqueous solubility (log P < 5, maximum 5 
hydrogen bond donors and 10 acceptors) (190). Based on a lack of violations of the Lipinski 
rules (table 3), DNDI-0690 is expected to exert oral bioavailability. DNDI-0690 is a small and 
moderately lipophilic molecule, indicating that is likely to pass across biological membranes, 
but also to have low aqueous solubility.   
Table 3: Physicochemical properties of DNDI-0690 
Parameter Value Violation of Lipinski’s rule of 5? 
Formula C18H15FN4O4 N/A 
Molecular weight 370.11 < 500: no 
LogP 3.27 < 5: no  
H-bond donor 0 < 5: no  
H-bond acceptor 7 < 10: no 
 
These in silico predictions about DNDI-0690 are in line experimental in vitro and in vivo results 
obtained earlier by DNDI: pKa=3.95, logDpH=7.4= 2.45, aqueous solubility = 114 µg/ml (2 µg/ml 
at pH 7.4) and an oral bioavailability of 20-36 % in male rats (PEG400 suspension, p.o.).      
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3.5.3. In vitro antileishmanial activity of DNDI-0690 
 
Table 4 shows the antileishmanial activity of DNDI-0690 against CL, as determined by 
microscopy using 72-hour intracellular antileishmanial assays using peritoneal mouse 
macrophages (data: Dr Katrien Van Bocxlaer, unpublished, reproduced with permission). The 
results from in vitro phenotypic screens show the broad-spectrum activity of DNDI-0690 
against a panel of CL-causing Leishmania strains and species in low micromolar 
concentrations. Note that during in vivo studies, we used the L. major MHOM/SA/85/JISH118 
strain, for which the IC50 was 4.58 µM (= 1.69 µg/ml).  
 
Table 4: in vitro antileishmanial activity of DNDI-0690 (ND: not determined) 
Leishmania parasite IC50 (µM) 
Species Strain DNDI-0690 AmB (+ control) 
L. major WRAIR 0.32 0.04 
L. major MHOM/SA/85/JISH118 4.58 0.05 
L. guyanensis WRAIR 0.68 0.05 
L. mexicana MNYC/BZ/62/M379 1.91 0.08 
L. panamensis Boynton 0.77 0.07 
L. aethiopica Karthoum <0.33 0.11 
L. tropica MHOM/AF/2015/HTD7 1.41 ND 
L. tropica WRAIR 1.6 0.03 
L. amazonensis DS Red 2 <1.11 ND 
 
3.5.4. Dose-response of DNDI-0690 in the L. major-BALB/c model of CL 
 
3.5.4.1. Aim  
 
DNDI-0690 is a clinical candidate for VL, but much preclinical PK, PD and PK/PD data in animal 
models of CL to support its development as a potential new medicine for this disease is 
lacking. The aim of this section was to characterize the dose-response effect of DNDI-0690 in 
the L. major-BALB/c model of CL as well as to link PK and PD parameters at the end of 
treatment.     
 
3.5.4.2. Materials and methods  
 
Animal model of infection. The experimental procedures to infect female BALB/c mice with 
L. major JISH118 promastigotes were identical to those described in chapters 3.1, 3.2, 3.3 and 
3.4. Twelve days after infection, when a 4-6 mm nodule had formed, treatment was started. 
Drugs and treatment. DNDI-0690 was administered once daily for 10 days via oral gavage 
(6.25, 12.5, 25 or 50 mg/kg suspension in polyethyleneglycol 400, PEG400). A head-to-head 
comparison with systemic paromomycin sulfate (PM, Sigma, UK), a positive control drug for 
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antileishmanial efficacy in this model (see chapters 3.1., 3.3. and 3.4.), was included at 
identical doses. However, because of the known poor oral bioavailability of PM (191), the 
systemic control was administered via the intraperitoneal rather than the oral route (as a 
solution in PBS). Drug solutions were made up fresh every day due to the unknown chemical 
stability of DNDI-0690 and PM in their respective vehicles.  
Lesion size. Lesion size during treatment was determined daily (average of length and width), 
as measured with digital callipers.     
Parasite load in the lesion. At the end of treatment (24 hours after administering the 10th and 
final dose), parasite load and DNDI-0690 drug levels were measured in lesion skin. The skin 
homogenization, Leishmania DNA extraction and qPCR method to quantify parasite burden 
in the lesion was as described in chapter 3.2, with the exception that parasite DNA extracts 
were not diluted 1/100 but used directly.  
DNDI-0690 extraction. Skin tissue was weighed and cut into fine, long pieces and placed into 
SureLock microcentrifuge tubes (StarLab, UK) together with 1 spatula (about 100 mg) of 2 mm 
zirconium oxide beads (Next Advance, UK) and 1 ml phosphate buffered saline (PBS, Sigma, 
UK). Samples were ground using a Bullet Blender Storm 24 (NextAdvance, UK) set at speed 12 
for 20 minutes to obtain a smoothly flowing homogenate and stored at -80 °C until further 
use. Drug extraction and protein precipitation were performed in 96-well plates: homogenate 
(50 µl) was added to 200 µl acetonitrile (HPLC grade, Fisher Chemical, UK) containing 200 
ng/ml tolbutamide as internal standard (analytical standard, Sigma, UK). Plates were shaken 
for 20 minutes at 900 rpm and centrifuged for 15 minutes at 13000 rpm at 4 °C. Sixty µl 
supernatant was collected and 60 µl HPLC-grade water was added. The mixture was stored at 
-80 °C until analysis. Blanks with and without internal standard tolbutamide were included, 
as were calibration samples with known concentrations of DNDI-0690 (similarly extracted and 
prepared after spiking 45 µl blank skin homogenate (derived from untreated BALB/c mice) 
with 5 µl working solutions of known DNDI-0690 concentrations in 1:1 acetonitrile:water 
(Sigma, UK).   
DNDI-0690 LC-MS/MS quantification. All samples were analyzed using a Shimadzu Nexera X2 
UHPLC/Shimadzu LCMS 860 at Pharmidex Pharmaceutical Services Ltd. A mobile phase (0.4 
ml/min) of water-0.1%formic (channel A) and acetonitrile-0.1%formic acid (channel B) was 
used to elute sample compound from a Kinetex column packed with 5-µm XB-C18 material 
column (2.1 mm by 50 mm at 50 °C; Phenomenex, UK). The mobile phase composition was 
initially 2% B, programmed to increase linearly to 95% B at 1.1 minutes after injection. After 
0.7 minutes at 90 % B, the composition was returned to its initial 2% B at 1.8 minutes post-
injection. DNDI-0690 was detected by monitoring transition of the parent molecule (m/z 370) 
to the fragment resulting from electrospray ionization (m/z 198.2). Analyte concentration was 
quantified against calibration standards prepared in matched control matrix, with aliquots of 
samples and standards being injected at 5 µl. The limit of quantification was 2 ng/ml.  
Statistical analysis. Analysis of variance (ANOVA) assuming Gaussian distribution (one-way 
for parasite load, repeated measures for lesion size) followed by Tukey’s multiple comparison 
tests was used to analyze differences between groups. All data are presented as means and 
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standard error of the mean (SEM). A p-value < 0.05 was considered statistically significant. All 
analyses were performed using GraphPad Prism version 7.02. 
Dose-response curves. Non-linear fit models (log(agonist) versus normalized response with 
variable slope) in GraphPad Prism version 7.02 were used to calculate ED50 and ED90 data. The 
response in treated groups was expressed as a relative reduction compared to untreated 
controls ((signal untreated – signal treated)/signal untreated *100 %). 
 
3.5.4.3. Results and discussion  
  
Figure 23 shows the dose-response effect of oral DNDI-0690 in comparison to the positive 
control drug PM (IP) at equivalent dose levels ranging from 6.25 to 50 mg/kg.  
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Figure 23: Dose-response effect of oral DNDI-0690 (left) and positive control drug intraperitoneal 
paromomycin (right) in the L. major –BALB/c model of CL. ** = p<0.01, *** = p<0.005, **** p <0.001 
in comparison to untreated control. 
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Over the course of daily treatment for 10 days, both DNDI-0690 and PM caused a significant 
(p<0.01) reduction in lesion size in comparison to the untreated control (PEG400). By day 10, 
both the 10 x 50 mg/kg oral DNDI-0690 and 10 x 50 mg/kg intraperitoneal PM dose regimens 
completely healed the lesion, as the size of the nodules was no longer measurable and only a 
faint scar remained (figure 19, photos). Significant reductions in parasite burden compared to 
the oral PEG400 vehicle alone (p<0.01) were observed for DNDI-0690 for doses above and 
including 12.5 mg/kg. However, the therapeutic efficacy of oral DNDI-0690 was inferior 
compared to intraperitoneal PM, as parasite load for PM at doses from 12.5 mg/kg were 
below the limit of quantification of 102 parasites per 2 µl sample. 
Table 5 shows the ED50 and ED90 values for lesion size and parasite load that was calculated 
based on the results of the dose-response study (figure 23) for oral DNDI-0690 and the control 
drug intraperitoneal PM.  
 
Table 5: Comparative 50 % and 90 % effective doses (lesion size, parasite load) for oral 
DNDI-0690 and the positive control drug intraperitoneal PM (means). 
 Lesion size Parasite load 
Drug ED50 ED90 ED50 ED90 
DNDI-0690 (p.o.) 4.5 mg/kg 18.7 mg/kg 4.7 mg/kg 17.9 mg/kg 
PM (IP) 6.2 mg/kg 22.8 mg/kg 5.9 mg/kg 6.3 mg/kg 
 
These values indicate that efficacy of DNDI-0690 (p.o.) in comparison to the positive control 
drug PM (IP) is comparable in terms of reduction in lesion size but inferior in terms of 
reduction in parasite load. Because no signs of toxicity or fatalities were observed at any 
tested dose level, no therapeutic index could be calculated. 
Finally, drug concentrations within the lesions of DNDI-0690 treated mice at the end of ten-
day oral treatment were determined (figure 24).  
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Figure 24: DNDI-0690 levels in the skin lesion (ng/g, 24 hours after 10 doses once daily) in relation to 
(i) dose level (left) and (ii) relative reduction in parasite load and lesion size compared to the 
untreated control (right). 
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A positive correlation (R2 =0.99) between dose level and DNDI-0690 levels in the infected skin 
was found (figure 24, left). Importantly, comparing the effects of different doses of DNDI-
0690, elevated drug concentrations in the lesions were associated with superior therapeutic 
efficacy (figure 24, right).   
In conclusion, the nitroimidazole DNDI-0690 is highly efficacious in the rigorous non-cure L. 
major BALB/c model of CL when administered daily for 10 days via the oral route. Doses 
around 5 mg/kg and 21 mg/kg showed 50% and 90% efficacy, respectively; 50 mg/kg knocks 
down parasite load by 95% and lesion size by 100% compared to the untreated control. There 
is a clear relationship between dose, intralesional drug levels (PK) and therapeutic response 
(PD). These findings justify a further preclinical investigation into DNDI-0690 as a potential 
oral treatment for CL. 
 
We then aimed to fully characterize the skin PK profile of the compound, to provide a basis 
for PK/PD modelling and prediction of safe, efficacious doses in humans. In the previous 
chapters, we used a skin homogenate approach to this end. This requires a high number of 
animals and measures total drug levels in all layers of the harvested lesion (epidermis, dermis, 
subcutaneous tissue, muscle) rather than only the pharmacologically active concentrations, 
i.e. the extracellular, unbound concentration of DNDI-0690 in the dermal interstitial fluid 
surrounding the parasitized macrophages. To overcome this issue, we optimized another 
technique to study drug distribution in animal models of CL, called skin microdialysis.  
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3.5.5. Skin microdialysis of DNDI-0690 
 
3.5.5.1. An introduction to skin microdialysis  
 
Microdialysis (MD) is a technique for sampling substances in the extracellular fluid in living 
tissue. The principle of MD was originally developed back in the 1960s in the field of 
neuroscience to study the biochemistry of the rodent brain. However, since the 1990s, it has 
been successfully applied for the sampling of substances (drugs, inflammatory mediators and 
endogenous molecules) in virtually any animal or human tissue, including muscle, heart, lung, 
brain, bone, adipose tissue, neoplastic tissue, blood and skin. Skin microdialysis (SMD) has 
been used to study topical drug penetration, PK/PD and/or tissue drug distribution for 
antibiotics, analgesics, antihistamines, non-steroidal anti-inflammatory drugs and local 
anaesthetics. Inflammatory mediators have been measured with SMD in the skin of healthy 
volunteers and patients with atopic dermatitis, burn injuries, psoriasis, cold urticarial, 
complex regional pain syndrome and cutaneous mastocytosis (191).  
For CL, the potential of SMD has not yet been explored, in neither animals nor humans. A  
particular advantage of SMD for CL relates to the fact that it can specifically measure the 
unbound, pharmacologically active drug concentration, directly in the interstitial space fluid 
of the dermis, the site that surrounds the Leishmania-infected macrophages. Moreover, SMD 
provides continuous, real-time monitoring of processes in the dermis, circumventing the need 
for invasive sampling at each desired time point as is the case for traditional methods such as 
skin blisters, skin stripping or skin biopsies (or necropsies in animals). In addition, these 
approaches have the disadvantage of measuring total drug tissue levels, which can be 
misleading because only the free concentration is available to exert antileishmanial activity 
(168, 169). Table 6 summarizes the differences between the skin homogenate approach used 
in earlier chapters and this innovative technique (for CL).  
 
Table 6: Comparison between skin homogenate and skin microdialysis to measure drug 
concentrations in animal models of CL 
  Skin homogenate  Skin microdialysis   
Procedure End-point, invasive:  
 1 animal = 1 time point 
 Variability between time points 
(different animals)  
Continuous, minimally invasive: 
 1 animal = multiple time points 
 Less variability between time points ( 
same animal) 
Measures   Drug and metabolites 
 Intra- and extracellular 
 Protein-free and -bound 
 Drug and metabolites 
 Extracellular  
 Protein-free 
Organ   Epidermis 
 Dermis 
 Hypodermis 
 
 Dermis 
Limitations   High number of animals 
 Pharmacologically inactive 
fraction is also measured  
 Not suitable for highly lipophilic or 
highly protein-bound drugs 
 Need for specialized equipment and 
technical skills 
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The basic principle of SMD (figure 25) consists of implanting a small probe in the upper dermis 
that is perfused with a physiological buffer, mimicking a small blood vessel in the tissue. The 
probe is essentially a hollow, semi-permeable membrane for dialysis: only molecules with a 
size smaller than the pores of the membrane (pore cut-off) can permeate into the dialysate. 
A tubing system connects the skin microdialysis probe to a perfusion inlet (syringe pump with 
a physiological solution) and a dialysis outlet (collector system). When the probe is perfused 
at a slow rate (0.5-10 µl/min), substances in the dermal interstitial fluid can passively diffuse 
across the membrane and compounds of interest can be recovered (192-194).   
 
 
Figure 25: Principles of skin microdialysis 
 
Here, we describe the development of an MD system for pharmacological evaluations in the 
L. major BALB/c mouse model of CL, which allows measurement of protein-free drug 
concentrations in the infected dermis (target site), as well as healthy control skin (control site) 
and plasma (systemic exposure).  
 
3.5.5.2. Skin microdialysis: development of the system 
 
The development of the MD for DNDI-0690 was a step-wise process:  
a) Assessing the suitability of DNDI-0690 for microdialysis 
b) Finding a method to restrain mice   
c) Testing of urethane anaesthesia on mice  
d) Inserting the microdialysis probe in skin tissue and tail vein 
e) A test run of the microdialysis system     
These steps are detailed in the following pages.  
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a) Assessing the suitability of DNDI-0690 for microdialysis  
 
During MD sampling, the continuous flow of physiological buffer through the probe causes 
incomplete equilibration between the drug concentration (C) in the dialysate and that in the 
medium surrounding the probe. This phenomenon depends on a number factors related to 
the drug (protein-binding, molecular weight, lipophilicity), the tissue (temperature, blood 
flow, metabolism) and the experimental microdialysis set-up (perfusate, flow rate and cut-off 
size, insertion depth, material, design and length of the probe) (193, 194). Relative recovery 
(RR) is defined as:  
 
RRdrug= C drug in dialysate / C drug in the medium surrounding the probe 
 
However, not all drugs have a suitable profile for MD. Lipophilic compounds with strong 
protein-binding properties have not only a low drug fraction that is available to permeate 
across the probe membrane but also a tendency to stick to the polymeric material of the 
tubing. This could result in low RR and a final sampled drug concentration below the lower 
limit of quantification of the analytical technique of choice. DNDI-0690 is a highly protein-
bound (95%), small (MW = 370 g/mol) and a relatively lipophilic (logP = 3) molecule. Before 
engaging in animal studies, the RR of DNDI-0690 first needed to be determined in vitro. After 
consultation with experts at the pharmaceutical company Pharmidex Pharmaceutical 
Services, a concentric cuprophane microdialysis probe with a 6 kDa cut-off value was 
purchased (MAB 1.2.4. Cu, Microbiotech, Sweden). The MAB1 series are small, fine and 
flexible probes designed for sampling of protein-free drugs in peripheral tissues (195).  
The aim of the initial in vitro recovery study for DNDI-0690 was to ensure (i) reproducible, 
stable recovery over a nanomolar concentration range and a 4-hour time period and (ii) 
detectable drug levels in the sampled dialysate based on the sensitivity of the available LC-
MS/MS method. 
 
Materials and methods  
Figure 26 shows the overview of the in vitro microdialysis set-up. A 1 ml syringe was filled 
with a filtered physiological buffer (artificial cerebrospinal fluid, aCSF) and mounted on the 
microdialysis pump (Harvard Apparatus 11 plus, UK). aCSF is the standard physiological buffer 
Pharmidex uses for initial RR studies. The probes were inserted in aCSF-filled vials (20 ml) 
containing magnetic stirrers in a 37 °C water bath (Sigma, UK), mimicking the in vivo 
environment. The system was connected via tubing (fluorinated ethylene propylene, FEP, 
Microbiotech Sweden) and tubing adapters (Microbiotech, Sweden) to the filled syringe on 
the perfusion pump and an automated refrigerated fraction collector (MAB 85, Microbiotech, 
Sweden) filled with HPLC vials (Thermo Fisher, UK).  
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Figure 26: In vitro skin microdialysis set-up 
 
Table 7 shows the phases and conditions of the experiment. The experiment was started at a 
flow rate of 2 µl/min and a sample collection interval of 15 minutes. After the first 15 minutes 
(aCSF phase), a 10 µl volume of 100 µg/ml stock solution of DNDI-0690 in DMSO was added 
to the vials to yield a final concentration of 50 ng/ml (50 ng/ml phase). After 90 minutes, the 
DNDI-0690 concentration in the vial was increased to 200 ng/ml by adding 30 µl of the same 
stock (200 ng/ml phase). Following another 90 minutes of sampling, the probes were 
transferred to a separate vial containing pure aCSF (wash phase).  
 
Table 7: Overview of the phases of the in vitro recovery experiment 
Phase  1) Equilibration  2) 50 ng/ml 
DNDI-0690  
3) 200 ng/ml 
DNDI-0690 
4) Wash-out 
Microdialysis probe 
is immersed in a  
vial containing:  
0 ng/ml DNDI-0690 
(pure aCSF) 
50 ng/ml DNDI-
0690 in aCSF  
200 ng/ml 
DNDI-0690 in 
aCSF 
0 ng/ml DNDI-
0690 (pure 
aCSF) 
Duration of the 
phase  
15 min  90 min 90 min 45 min 
Time from the start 
of the during 
experiment:  
0 – 15 min 15 – 105 min  105  195 min  195 – 240 min 
 
Finally, 10 µl acetonitrile was added to the 30 µl samples in the HPLC vials and analyzed (no 
further sample preparation) using the same LC-MS/MS method used for quantification of 
DNDI-609 levels in skin homogenate extracts (see 3.5.4.2).         
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Results 
Figure 27 shows the results of the in vitro experiment. No DNDI-0690 is detectable in the 
dialysate in the first 15 minutes of sampling (equilibration). When the concentration of DNDI-
0690 in the vial within which the MD probe is immersed is increased to 50 ng/ml, drug levels 
in the dialysate rapidly elevate and remain at around 20 ng/ml throughout the 90 minutes of 
sampling. At a concentration of 200 ng/ml DNDI-0690 in the vial, a similar pattern is observed 
with dialysate levels rising to 50 ng/ml. Finally, when the probe is transferred to a vial with 
only pure Ringers physiological solution, DNDI-0690 concentrations in the dialysate return to 
the baseline levels, i.e. before the addition of drug (washout phase). 
Unfortunately, the results for the 50 ng/ml and 200 ng/ml DNDI-0690 samples (taken directly 
from the vials during the experiment) were unexpected and invalid (50 ng/ml in vial ~ 130 
ng/ml; 200 ng/ml ~ 120 ng/ml). This was likely the consequence of an experimental mistake 
in labelling, sampling or analysis. Hence, the exact RR for DNDI-0690 from this particular MD 
probe and set-up could not be calculated (Cdrug in dialysate known, but Cdrug in the medium surrounding the 
probe unknown). However, it was clear that there was a certainly some recovery of DNDI-0690, 
because the drug was detectable in dialysate and the drug concentration pattern changed 
throughout the study as was expected for the different phases (equilibration, 50 ng/ml, 200 
ng/ml and wash).  
 
Figure 27: In vitro recovery of DNDI-0690.  
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In conclusion, the exact value of the RR of DNDI-0690 in this MD setting could not be 
determined. The LC-MS/MS method is sensitive enough to detect DNDI-0690 as the dialysate 
concentrations were above the lower limit of quantification of 2 ng/ml. A future experiment 
is required to determine RR, in conditions closely mimicking the in vivo set-up (Ringers 
physiological buffer, the most commonly used perfusate for skin MD studies (193, 194); vial 
temperature of 32 °C for skin; 37 °C for blood).  
 
b) Finding a method to restrain mice 
After confirming that DNDI-0690 is an eligible candidate for MD, the next step was to find a 
method to use the system in BALB/c mice. All animal experiments described in the following 
work were conducted under license X20014A54 according to UK Home Office regulations 
under the Animals (Scientific Procedures) Act 1986 and EC Directive 2010/63/E. 
Under ideal conditions, the experiment would be performed in awake animals, as anaesthesia 
might interfere with physiology and thus PK profile of the drug candidate. At the same time, 
the small and fragile MD probes needed to remain undamaged and securely in place 
throughout sampling of drugs in skin and blood. Hence, we needed a method to fully restrain 
mice and prevent them from interfering with the MD set-up.  
Special restraining jackets (Dermal Inserts for Rodents, Lomir Biomedical Inc, Canada) were 
ordered and tested as a means to immobilize the mice. However, the animals were clearly 
intimidated and stressed while wearing them. When the jackets were placed within the 
rodent cage (so the mice could get more familiar with their smell and presence), the animals 
started nibbling the plastic, posing a potential hazard to their health (see figure 28). Combined 
with concerns from the ethical and animal welfare committee about the jackets, it was 
decided to instead anaesthetize the mice during the MD experiments instead of physically 
restraining them.      
 
 
Figure 28: Lomir Biomedical rodent jackets on BALB/c mice 
 
 
 
c) Testing of urethane anaesthesia on mice  
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A number of anaesthetics were considered based on ease of use, duration of effect and 
interference with mouse cardiovascular function (as this can directly affect the PK of oral 
drugs). Gas isoflurane anaesthesia causes rapid induction, but could interfere with animal 
physiology (196) and requires regulation of gas and oxygen flow in the midst of an already 
complex and time-sensitive microdialysis experiment. The most common injectable 
anaesthetic ketamine (with or without xylazine) increases blood pressure and heart rate and 
typically causes only short-term hypnosis (30-60 minute), meaning repeated dosing 
throughout the experiment (197). A better alternative was urethane: an injectable 
anaesthetic providing long-term narcosis (6-10 hours) at doses of 1-2 g/kg (IP) that produces 
minimal effects on the cardiovascular system and thus plasma PK (198-200). Due to its 
carcinogenicity, it is only used for terminal anaesthesia and strict health and safety 
procedures are required for preparation, storage and waste disposal. While it has been used 
successfully in rats (198-200) and various mouse strains (201-203), no evidence of use in 
BALB/c mice could be found in the scientific literature. We, therefore, performed a pilot study 
to test the anaesthetic effects of urethane on two female BALB/c mice. After discussion with 
the Named Veterinary Surgeon from the Royal Veterinary College in London, it was concluded 
that no analgesia was needed to accompany urethane anaesthesia because the dermal probe 
insertion procedure is minimally invasive and animals would not be allowed to recover. In 
addition, we gathered advice from colleagues at UCL Ear Institute (who had experience in 
working with urethane) before starting the pilot study.   
 
The aim of the study was to gather information about the (i) effects of urethane anaesthesia 
(induction time, narcosis period, complications), (ii) potential issues related to oral gavage 
under anaesthesia (needed for drug administration of DNDI-0690) and (iii) technical 
challenges for the placement of the MD probes in skin tissue and/or blood vessels.    
Urethane (Sigma, UK) was prepared in sterile water 20 % (w/v) wearing personal protective 
equipment in a chemical hood and stored in the dark for one week at room temperature 
before use. Two female BALB/c mice with L. major lesions on the rump (infection method: 
see chapters 3.1, 3.2, 3.3. and 3.4.) administered either 1.6 or 1.9 g/kg urethane (IP) and left 
in a dark cage in a quiet environment. Induction of anaesthesia was successful at both doses 
within 10 minutes and animals were placed on a preheated hot plate (37 °C) covered in paper 
tissue. Rehydration solutions were administered after 1 hour and 4 hours (0.1 ml PBS, SC). 
Temperature (IR thermometer) and breathing (visual check of the number of breaths per 15 
seconds) were measured every 30 minutes. Over the course of the experiment, mice 
remained anaesthetized for 8 hours, though random movements of head and paws were 
occasionally observed, especially when exposed to sudden visual or auditory stimulation. As 
seen in figure 29, the body temperature of the rump skin remained stable (32-33°C) for both 
urethane doses and breathing patterns were in the expected range (25-40 breaths per 15 
seconds, based on advice UCL colleagues).   
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Figure 29: Clinical monitoring of temperature (left graph) and breathing patterns (right graph) of 
BALB/c mice under the anaesthetic effects of urethane 
 
Finally, we administered 200 µl of sterile water by oral gavage to the anaesthetized mice. As 
long as given carefully and the head of the animals was slightly raised, the limited swallowing 
reflexes of the animals under the effects of urethane did not seem to cause a risk of 
suffocation or incomplete dosing by vomiting.  
In conclusion, 1 x 1.6 g/kg urethane (IP), the lowest effective dose, induces 8 hours 
anaesthesia in BALB/c mice without hindering oral drug administration. This anaesthetic 
regimen was used in the following experiments. 
  
d) Inserting the microdialysis probes in skin and tail vein 
We then tested insertion of MAB 1.2.4. MD probes (Microbiotech, Sweden) in lesion skin 
(target site) and in the tail vein (system exposure).  
First, the insertion of the probes in the lesion skin was attempted (figure 30, bottom row). 
The rump skin tissue containing the lesion was held in place with forceps. A 22G needle was 
placed intradermally and stuck through (in and out) the skin to serve as a guide cannula.  
The probe was carefully placed it inside the needle tip sticking out of the skin. The needle 
was withdrawn from the skin while holding the probe shaft, leaving the probe inserted into 
the lesion. The probe shaft was then secured in position by applying tape and contact glue. 
After the animals were humanely culled (pentobarbital), we surgically removed the lesion 
skin. It was clear that the probe had been inserted into the lesion as intended: in the middle 
of the inflammatory mass of the dermis where the Leishmania parasite resides. Finally, we 
recovered the probe from the skin.     
We then inserted the probe in the tail vein (figure 30, top row). A glove filled with warm 
water (~37 °C) was placed on the tail for 2 minutes to induce vasodilation. Again, a 22G 
needle was inserted through the vein (in and out) and the probe was inserted inside the 
needle. Wrapping tape around the tail appeared sufficient to keep the probe securely in 
place. 
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Figure 30: insertion of the microdialysis probe in the tail vein and the lesion skin. Top row (left to 
right): microdialysis probe, probe inserted in tail vein, probe inserted in tail vein secured by tape. 
Bottom row (left to right): probe inserted in lesion skin secured by glue, detail confirming 
intradermal insertion of the probe in the inflammatory mass of the lesion, probe after removal from 
lesion tissue. 
 
e) A test run of the microdialysis system     
After successful placement of probes in lesion skin and tail veins, we set up a very basic 
microdialysis flow channel to familiarise ourselves with the set-up, practice troubleshooting 
and control the sample volume (figure 31). A 1 ml syringe filled with the filtered Ringers 
physiological solution was placed on the perfusate pump and connected via FEP-tubing and 
adapters to the probe inlet. The probe was inserted intradermally within the lesion on the 
rump of the mice. The probe outlet tubing was placed in collection vials to check the sampled 
volumes. Occasional leakage of the system was observed, which could be prevented and 
resolved by moving the tubing adapters and changing the tubing. Finally, the pump was 
started at 2 µl/min and the volumes collected every 15 minutes for 1 hour. The volumes were 
correct (30 µl) and reproducible.        
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Figure 31: Essential set-up of the in vivo skin microdialysis test experiment 
 
 
3.5.5.3. Lesion, control skin and tail vein microdialysis after oral dosing of DNDI-0690 
 
To study the skin and plasma PK profile of oral DNDI-0690, we performed microdialysis in the 
lesions, healthy control skin and tail veins of three L. major-infected BALB/c mice. Figure 32 
gives an overview of the experiment set-up.  
 
Materials and methods  
Microdialysis set-up. Nine microdialysis channels were set-up as follows. A syringe with the 
filtered Ringers physiological solution was mounted on Harvard Apparatus pump set at a flow 
rate of 2 µl/minute. The syringe was connected via FEP-tubing and adapters (Microbiotech, 
Sweden) to the inlet of the microdialysis probe (MAB 1.2.4. CU, Microbiotech, Sweden) and 
the probe outlet was linked via FEP-tubing to the needle of the automated fraction collector 
(MAB 85, Microbiotech, Sweden) that was filled with empty HPLC vials (0.2 ml crimp top, 
Thermo Scientific, UK). At a collection interval of 30 minutes, sample volumes were 
consistently 60 µl, indicating the desired perfusion of the microdialysis probes in the bijou 
filled with Ringers.  
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Figure 32: Set-up of lesion, control skin and microdialysis after administration of oral DNDI-0690 in 
the L. major-BALB/c model of CL. A: microdialysis probe (6 kDa cut-off). B: Microdialysis set-up (9 
channels) – pumps (left), mice on a hot plate (middle) and automated fraction collectors (right). C: 
Mice after insertion of probes. D: Detail of one mouse after insertion of microdialysis probes in the 
lateral tail vein (red arrow), dermal layer of the lesion skin (orange arrow) and dermal layer of 
healthy control skin (green arrow). 
 
Animals. L. major-infected BALB/c mice (n=3) each received 1.6 g/kg urethane (IP): deep 
anaesthesia (no hind paw reflex) was induced within 10 minutes. After anaesthesia, 200 µl 
Ringers physiological solution was administered via neck scruff (SC) to prevent dehydration. 
Mice were placed on a preheated hot plate to maintain body temperature (37 °C). MD probes 
were placed in the positions: the dermal skin layer of the CL lesion on the rump, the dermal 
skin layer of the healthy control skin higher up on the back and the tail vein. Following this 
order, three probes were installed per mouse.  Probes were secured with tape and perfused 
with a physiological buffer. The animals were allowed to recover from any trauma caused by 
probe insertion for 30 minutes before drug administration. 
Drug administration, animal monitoring and sampling. Then, a single dose of 50 mg/kg DNDI-
0690 (200 µl suspension in PEG400) was administered via oral gavage (t0 of the PK study). 
Temperature, breathing pattern and behaviour of the anaesthetized mice were monitored 
constantly; no abnormalities were observed in the following 5 hours of MD sampling. After 3 
hours, another 200 µl Ringers physiological solution (SC) was administered via the neck scruff 
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for rehydration. At a collection interval of 30 minutes, sample volumes were consistently 60 
µl, indicating the desired perfusion of the intradermal microdialysis probes. The experiment 
was terminated after 5 hours of microdialysis sampling and mice were humanely culled by 
pentobarbital overdose.  
Samples. Samples (60 µl) were collected from the fraction collector every 30 minutes. 20 µl 
acetonitrile (ACN) was added immediately and the vials were sealed with a crimp cap (Thermo 
Scientific, UK). A calibration curve ranging from 100000 to 2 ng/ml was prepared as follows: 
6 µl of known working standard of DNDI-0690 in ACN:H2O (1:1) was added to 54 µl of blank 
Ringers solution and 20 µl ACN. For blanks, 6 µl ACN:H2O (1:1), 54 µl plain Ringers solution 
and 20 µl ACN was used. Samples were stored at – 80 °C until LC-MS/MS analysis (Pharmidex).  
Analysis. Cmax, Tmax and AUC0–48 values for skin were calculated using GraphPad Prism, version 
7.02.     
 
Results 
Figure 33 shows the PK of DNDI-0690 in the L. major-BALB/c model of CL after oral 
administration of a single dose of 50 mg/kg, as assessed by MD.  
In plasma, the Cmax was 133 ± 32 ng/ml 2 hours after drug administration, indicating the time 
needed for maximal absorption from the gastrointestinal tract into systemic circulation. Due 
to the lack of a 24 or 48-time point, the full DNDI-0690 concentration-over-time profile could 
not be studied during this MD experiment. As a result, no exact T1/2 (> 4 h), Cl, Vd and AUC0-
∞, could be calculated.   
In the peripheral tissues of the healthy skin (control) and the CL lesion, drug accumulation 
was lower and slower compared to that in plasma. DNDI-0690 exposure (based on AUC0-5h 
values) in the lesion (115 h.ng/ml) was about 1/3 of that in healthy skin (346 h.ng/ml) and 1/5 
of that in plasma (500 h.ng/ml). Maximal drug concentrations in healthy skin (Cmax =93 ± 42 
ng/ml at 4.5 h) were 3-fold higher compared to those in lesions (Cmax =35 ± 9 ng/ml at 5h). 
DNDI-0690 concentrations in skin tissues increased gradually over time after administration, 
but were near maximal after 2-3 hours, indicating relatively rapid drug distribution from 
systemic circulation.    
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Figure 33: Unbound dermal tissue and plasma concentration-over-time profile of DNDI-0690 after 
oral administration of a single 50 mg/kg dose to L. major-infected BALB/c mice (n=3). Photo: PK 
sampling sites (microdialysis): plasma (red arrow), healthy control skin (orange arrow) and lesion 
(yellow arrow). 
 
3.5.6. Discussion  
 
In this chapter, we have evaluated the PK and PD properties of a new oral drug candidate, the 
nitroimidazole DNDI-0690, in a standard mouse model of CL.  
An MD technique was optimized to measure unbound (pharmacologically active) drug 
concentrations in the dermal layer of the skin lesion (site of action) and other compartments.  
We have shown that DNDI-0690 accumulates relatively rapidly within skin lesions: near-
maximal (for a single dose) nanomolar unbound concentrations are achieved within 2-3 hours 
of oral dosing. In addition, DNDI-0690 shows different PK profiles in diseased skin, healthy 
skin and plasma. In the 5 hours following oral dosing, drug exposure in the lesion is about 5-
fold lower than in plasma, and, unexpectedly, about 3-fold lower than in control skin. In 
contrast, we already showed that the inflammation at the infection site in CL enhances local 
drug accumulation after intravenous administration of different formulations of AmB 
(chapter 3.2, 3.3. and 3.4). Unbound DNDI-0690 concentrations in the dermal interstitial fluid 
could be lower in diseased than in healthy skin because higher amounts of drug might reach 
the skin tissue from the bloodstream (increased vascular permeability, vasodilation), but a 
large drug faction could then be bound to inflammatory proteins or ingested by the many 
immune cells in the dermis (chapter 3.4). As neither protein-bound nor intracellular drug 
fractions are measured by MD, this could explain the ultimately lower extracellular exposure 
of DNDI-0690 at the site of infection compared to uninfected counterparts. In any case, this 
finding illustrates once again the impact of the immunohistopathology of CL on local drug 
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accumulation in the skin. Differences between AmB and DNDI-0690 PK results could be 
related to the different sampling methodologies (respectively skin necropsies and MD).      
Comparing PK outcomes for DNDI-0690 obtained by MD and skin necropsy sampling (followed 
by LC-MS/MS), maximal drug concentrations for MD (5 hours after 1 x 50 mg/kg = 35 ng/ml) 
are about 9-fold lower than for skin necropsies and homogenates (24 hours after 10 x 50 
mg/kg = 300 ng/g). Taking into account single versus 10-fold dosing, this difference is smaller 
than expected: homogenates measure total drug levels (protein-bound + protein-free + 
intracellular + extracellular), while MD measures only the free extracellular fraction of the 
highly protein-bound (95%) compound DNDI-0690. A homogenate-based repeat of the DNDI-
0690 PK study could fully validate MD as a new PK technique as well as discriminate drug 
factions in the skin (in relation to their effects) in CL drug research. Important advantages of 
MD are (i) measuring only protein-free extracellular concentrations (ii) decreasing variability 
in outcomes (one mouse can yield several PK time points) and (iii) reduction in the numbers 
of animals required for PK research. In our specific case, where we sampled every 30 minutes 
for 5 hours, MD on an individual mouse can yield the scientific data equivalent to the use of 
10 rodents with the necropsy-based technique, a 90 % reduction in the numbers of animals.  
To make pharmacological sense of PK data, it must be interpreted in relation to PD 
parameters. We showed a fundamental basis for a PK/PD relationship for DNDI-0690, a clear 
relationship between dose, intralesional drug concentration (PK) and efficacy (PD) in the 6.25 
to 50 mg/kg range at the end of 10-day treatment once daily. Using MD, we demonstrated 
that maximal drug levels in the lesion within 5 hours after 1 x 50 mg/kg drug administration 
to L. major-infected mice  (35 ± 9 ng/ml) are around 48-fold lower than the in vitro IC50 for L. 
major JISH118 (1690 ng/ml) and 3-fold lower for L. major WRAIR (118 ng/ml). However, the 
actual drug concentrations at the dermal site of infection site should be higher than those 
observed: the raw experimental MD results have not yet been corrected for incomplete 
recovery of DNDI-0690. The exact in vitro  relative recovery is first needed to allow this. In 
addition, during the in vivo dose-response study (figure 24), about 5 to 6 oral doses of 50 
mg/kg DNDI-0690 once daily were required to significantly reduce lesion size in comparison 
to the untreated control. This might indicate that the unbound DNDI-0690 concentrations in 
the hours following 1 x 50 mg/kg are insufficiently high for immediate parasite elimination. 
Repeated or more frequent/higher dosing of DNDI-0690 could be required for maximal 
efficacy in CL. However, because the degree of inflammation (in addition to parasite load) 
determines lesion size, it is a possible confounder the interpretation of antileishmanial drug 
activity.  Immunological healing of the lesion could be delayed in comparison to the time at 
which the dermal parasites are killed by DNDI-0690. Rate of kill studies, for example, by daily 
in vivo imaging during treatment with 10 x 50 mg/kg DNDI-0690, can help to clarify this 
important issue.  
Future plans and perspectives for the further preclinical development of DNDI-0690 as a 
promising drug for the treatment of CL is included in the final thesis discussion (chapter 5). 
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4. SUMMARY OF KEY FINDINGS  
 
With the aim of supporting the successful discovery and development of much needed new 
treatments for the parasitic skin infection CL, this thesis provides a strategic approach and a 
coherent set of R&D methodologies to evaluate PK, PD and PK/PD properties of preclinical 
drug candidates in animal models of disease.  The main findings of the work are:  
1. The poor translational outcomes of the current predictive models for phenotypic 
screening of drug activity in CL are illustrated by the lack of in vitro-in vivo correlation 
for a new drug combination of chloroquine and paromomycin. More biologically 
complex models and associated research methodologies are needed to overcome high 
compound attrition rates along the R&D pathway.   
2. We compared the effects of three different pharmaceutical formulations of the 
standard drug amphotericin B (the unilamellar liposome AmBisome, the multilamellar 
liposome Fungisome and the non-liposomal deoxycholate salt Fungizone) in L. major-
BALB/c mouse models of CL. The therapeutic efficacy of AmBisome > Fungisome > 
Fungizone in CL, due to higher tolerated doses and increased drug accumulation at 
the site of infection. Moreover, there was a clear relationship between dose, 
concentration (LC-MS/MS drug levels based on skin homogenates) and response 
(qPCR parasite load) for AmBisome. This provides a basis for the rational design of 
better clinical dose regimens, as well as a model for the PK/PD evaluation and 
comparisons of new drug candidates. Moreover, encapsulation of antileishmanial 
compounds in AmBisome-like liposomes (vesicle size around 80 nm, stable in the 
blood) could be a strategy to reduce drug toxicity and passive targeting of the dermal 
site of infection. 
3. We then further investigated the role of pathology in CL on PK (and PK/PD) of 
AmBisome in murine CL. Local tissue inflammation at the dermal site of infection has 
a profound effect on the PK of AmBisome and contributes to a variable in vivo efficacy 
between L. major and L. mexicana. This is related to pathophysiological alterations in 
diseased skin, such as increased vascular permeability of the dermal capillaries and 
tissue infiltration of inflammatory cells. 
4. The drug candidate DNDI-0690, a nitroimidazole compound developed by the Drugs 
for Neglected Diseases initiative for VL, also exerts significant efficacy in the L. major-
BALB/c model of CL when given daily via the oral route for ten days. We observed a 
dose-concentration-response effect in the 6.25 to 50 mg/kg range; the highest DNDI-
0690 dose reduced parasite load by 95% and lesion size by 100% in comparison to 
untreated controls. Additionally, we confirmed the accumulation of DNDI-0690 at the 
dermal site of infection within 2-3 hours after oral dosing using microdialysis.  
Microdialysis holds much untapped potential for (pre)clinical drug distribution and 
biomarker studies for CL. Finally, while more preclinical research on efficacy, safety, 
PK and PK/PD is required, our data support further investigation of DNDI-0690 as a 
promising drug candidate for the oral treatment of CL.  
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5. GENERAL DISCUSSION: RECAPITULATION AND FUTURE PERSPECTIVES 
 
There has been significant recent progress in the discovery and development of new drugs 
for VL, but despite the high unmet medical need, there has been limited advancement for CL. 
The dermal site of action (rather than spleen, liver and bone marrow for VL) and different 
drug sensitivities of more than 15 cutaneous Leishmania species (rather than L. donovani or 
L. infantum for VL) illustrate the need for new methodologies to support and accelerate drug 
development for CL. In this PhD thesis, we have: 
1. Confirmed known scientific challenges and problems in current R&D for CL.  
2. Developed new methods to study skin PK and PK/PD in animal models of CL  
3. Applied these new research tools to evaluate and select three new candidate 
treatments 
4. Provided rational strategies for future CL drug development  
 
In addition, the lessons and approaches described herein might also be relevant for finding 
novel treatments for different inflammatory skin disorders (psoriasis, melanoma, dermatitis) 
or diseases caused by other intra-macrophage pathogens (TB, brucellosis, melioidosis, Q-
fever, listeriosis). 
 
5.1.  Scientific challenges and problems in current R&D for CL  
 
The variable treatment response in CL based on the different causative species of the 
Leishmania parasite is a well-documented challenge for drug discovery and development for 
this disease (144, 145). We confirmed this issue in chapters 3.1. and 3.4.: both the standard 
antileishmanial drugs PM and LAmB exert a superior in vivo efficacy against L. major 
compared to L. mexicana, at identical dose levels and in the same animal model (BALB/c 
mouse). In addition, we also demonstrated, for the first time, that such differences in 
therapeutic efficacy of LAmB could result not only from PD parameters (the variable drug 
susceptibility of Leishmania species) but also from PK factors. We showed how the more 
severe local inflammation in L. major compared to L. mexicana CL causes enhanced drug 
accumulation in the lesions, contributing to the superior efficacy of LAmB against the Old 
versus the New World parasite (chapter 3.4). These findings indicate the need to test novel 
compounds against a panel of species and recent clinical isolates of Leishmania during early 
drug development, not only in vitro (PD) but also in vivo (PK and PD). With more than 15 
causative Leishmania species and simple, diffuse, mucosal and chronic forms of the CL, it is 
unlikely that one drug alone will prove to be a panacea, let alone in a single pharmaceutical 
formulation or standardised clinical dose regimen suitable for disease treatment in the Middle 
East, Latin America and other endemic settings.  
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Another issue in R&D for CL is the poor translational outcomes of the current in vitro assays 
used to test for antileishmanial activity, resulting in high compound attrition rates (204). 
Indeed, the promising activity of a new drug combination of paromomycin and chloroquine 
in the static, 2D intracellular amastigote model could not be replicated in animal models of 
neither L. major nor L. mexicana CL (chapter 3.1.). To predict antileishmanial activity in vivo, 
i.e. parasite survival in response to continually changing drug concentrations in the 
biologically complex environment of the dermis, the following in vitro and ex vivo models 
could be more relevant: 
 In vitro 3D macrophage and/or skin culture models. Experimental in vitro models of 
wound healing (205), atopic dermatitis (206), psoriasis (207) and melanoma (208) are 
already available, mostly based on seeding fibroblasts and then keratinocytes on a gel 
to create a simplified but skin-like tissue structure. However, creating 
immunocompetent skin models remains fundamentally and technically challenging at 
present (209). With ongoing advancements in 3D printing and tissue engineering, such 
models containing macrophages infected with Leishmania (transfected with a 
reporter gene) might soon play a role in the testing of new treatment options for CL.  
 Ex vivo skin models. Models of bacterial biofilms growing on porcine skin have already 
been used for the evaluation of antibiotics (210). However, because the pig skin tissue 
is no longer viable, Leishmania would be unlikely to infect the resident macrophages 
or to survive long-term in this model. While no ex vivo skin model is available for CL, 
antileishmanial drug evaluations for VL have been performed in lymph node tissue 
(211) and spleen (212) to better simulate pathophysiological infection environments.   
 In vitro PK/PD models. Recently, our group developed a perfusion system using 
interstitial fluid flow rates and L. major-infected macrophages. Interestingly, for 
several standard antileishmanial drugs, EC90 values were lower for those derived from 
flow rather than in static systems (213). While further work is needed to simulate the 
effect of dynamic drug exposure on parasite survival, such models have great potential 
to study time-kill behaviour, PK/PD-drivers of efficacy, synergy between drug 
combinations and susceptibility breakpoints (214).  
 
All of these models are technically challenging, low-to-medium throughput and relatively 
expensive, and would hence not be suitable for high throughput screening and hit 
identification. However, they could hold potential for compound evaluation in hit-to-lead, 
lead selection and preclinical phases, as they are expected to perform better at predicting in 
vivo efficacy than biologically simpler and/or static models. This brings us to another issue in 
CL drug research: measurement of the predictive value of these preclinical models. Validation 
of the models, by correlating preclinical predictions with human outcomes, is difficult, 
because few clinical candidates are being advanced into clinical trials and many CL drugs are 
repurposed from VL. Overall, such translational gaps between in vitro and in vivo, as well as 
between preclinical and clinical phases, highlight the needs for new PK, PD and PK/PD models 
and methodologies for CL drug development.  
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5.2. New PK and PK/PD drug development methodologies for CL 
 
In this work, we established and optimized a number of new methods to evaluate in vivo skin 
tissue penetration (PK) and antileishmanial (PD) properties of candidate compounds to assist 
in early drug development for CL (hit-to-lead, lead optimization, preclinical studies). Such R&D 
techniques, that could reduce attrition rates related to poor PK, PD and PK/PD characteristics, 
include:     
 A method to study the plasma and skin PK of antileishmanial drugs in animal models 
of CL, based on combined sampling by skin necropsies and tail vein bleeding, followed 
by drug extraction and LC/MS-MS quantification (chapter 3.2, 3.3 and 3.4.). This 
approach was used to characterize the plasma and skin PK of a standard 
antileishmanial drug formulation (LAmB) in the classic L. major-BALB/c model of CL 
(chapter 3.2). In addition, it provided the basis for a simplified but fundamental 
understanding of PK/PD of LAmB in CL. At the end of treatment, there was a clear 
correlation between dose, concentration and response. In addition, intralesional 
levels of the concentration-dependent drug AmB (5-50 µg/g) were above the in vitro 
IC50 value (≈ 2 µg/ml in 72-hour intracellular assays, chapter 3.1). A limitation of this 
necropsy approach for PK is that it requires a high number of animals and that it might 
lead to erroneous conclusions about drug levels, as these are a cumulative total 
(protein-bound/free, intracellular/extracellular) rather than only the 
pharmacologically active concentrations.   
 A method to study the plasma and skin PKs of antileishmanial drugs in animal models 
of CL, based on combined sampling by skin and plasma microdialysis, followed by 
drug extraction and LC/MS-MS quantification (chapter 3.5.). Compared to the 
technique described above, skin microdialysis provides continuous real-time 
monitoring of unbound drug concentrations in the infected dermis and circumvents 
the need for invasive end-point sampling at each desired time point. Hence, once 
established and optimized, MD can reduce the cost in early drug development 
because the number of animals is lower and a wide range of data (PK, possibly PD) can 
be gathered from a single mouse, reducing variability. In this work, we have used MD 
to confirm the suitable PK profile of the drug candidate DNDI-0690 for further 
development for CL. Apart from such applications for preclinical animal models for CL, 
there is also unexploited potential in humans. MD has already been used extensively 
to study various skin diseases in the clinic, but not CL, MCL or PKDL. Possible future 
applications of MD in leishmaniasis research could include:   
o MD: drug distribution in the skin. Because little is known about the PK and PD 
properties of the current antileishmanial drugs, treatment regimens are empirical 
and based on the maximum tolerated doses, rather than rationally designed and 
optimized. This leaves patients at risk of drug-related adverse and toxic effects, 
therapeutic failure and relapse of PKDL after initial cure. Monitoring of drug 
concentrations (and biomarkers, see below) in the infected skin of individual 
patient could help to provide clinicians with directions for a more effective, shorter 
or safer treatment of CL. MD can also be a tool to predict intralesional drug 
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exposure from blood samples, once the plasma-skin drug transfer process has 
been fully characterized and mathematically described. Such an approach was 
successfully used to understand skin PK of amoxicillin and cefuroxime for bacterial 
infections (215).  
o MD/PET: intracellular drug distribution in the skin. While SMD can be used to 
measure extracellular drug concentrations in the dermal interstitial fluid, ideally 
we are interested in intracellular drug levels, the true site of action for Leishmania. 
On the other hand, positron emission tomography (PET) and magnetic resonance 
spectroscopy (MRS) can track total drug (intracellular, extracellular) levels of 
radiolabelled drugs. The combined use of MD with such complementary non-
invasive drug imaging methods can allow the exploitation of the strengths of the 
individual techniques. Indeed, the difference of total (PET/MRS) and extracellular 
(MD) drug levels in tissue gives an estimation of local intracellular drug 
concentrations (216, 217). In this way, MD/PET has been applied to determine 
intracellular drug distribution of 18F-labelled ciprofloxacin in human muscle (218). 
Dermal MD in the skin lesion during treatment with a radiolabelled drug 
(candidate) could be a potential tool for translational drug development and 
clinical research in CL. 
o MD/IVIS: real-time PK/PD. A powerful combination of methods for CL preclinical 
drug evaluation would be to match MD directly with in vivo imaging (IVIS) of 
bioluminescent Leishmania (219, 220). This way, the drug exposure at the target 
site can be coupled directly to the magnitude and rate of parasite killing. Apart 
from continuous PK and PD assessment within the same animal, the outcomes 
would allow an understanding of PK/PD based on in vivo efficacy for PD, rather 
than relying on in vitro IC90 values. Understanding of PK/PD relationships with 
simulation and modelling can help to predict safe and effective dose regimens 
during Phase II and III clinical trials, to ultimately saving costs and time to 
successfully deliver a new medicine. 
o MD: therapeutic biomarkers. During PK studies for DNDI-0690, we used MD 
probes with a small cut-off size (5 kDa) to specifically measure only the protein-
free drug level in plasma and skin tissue. Pores with larger cut-off sizes (such as 
100 kDa) could be used to not only sample drugs from the interstitial fluid of the 
infected dermis, but also therapeutic biomarkers such as inflammatory cytokines, 
parasite antigens and macrophage activation markers (221). The search for 
suitable therapeutic biomarkers that can indicate treatment success or predict 
failure and relapse in leishmaniasis treatment is an ongoing challenge (222).  
o MD: inflammatory mediators. Dermal microdialysis is a well-explored research 
tool to sample cytokines, chemokines and inflammatory mediators and study 
inflammation, physiology and pathology in atopic psoriasis, contact dermatitis, 
urticaria, burn injuries, inflammatory pain and wound healing (223). A similar 
approach could advance our understanding of fundamental immunology and 
inflammation in CL, MCL and PKDL, possibly contributing to the development of a 
preventive or therapeutic vaccine.       
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o Reverse MD: drug delivery. Rather than perfusing the probe inserted in the tissue 
of interest with a physiological buffer, it could also be used as a delivery system to 
allow drugs in the perfusion fluid to diffuse into the target site. While such a 
reverse MD approach has already been used for drug delivery to tumours in 
hospitalized cancer patients (224), it is highly unlikely that it would be feasible, 
practical or cost-effective for the treatment of CL.      
 
 An Evans Blue assay to determine the vascular permeability of the blood vessels at the 
dermal infection site in animal models of CL. This is an important pathophysiological 
parameter affecting systemic drug delivery (chapter 3.4.). More sensitive and informative 
methods from the field of cancer research, such as using fluorescent dextrans of particular 
sizes to determine pore-cut-off size and other blood vessels properties (225), have not yet 
been used in CL.    
 A qPCR assay for the detection of parasite burden in CL lesions, based on amplification of 
pathogen RNA rather than DNA (chapter 3.3). This reaction involves an additional step 
where target RNA is first transformed into complementary DNA. Typically, in comparison 
to DNA-based assays, RNA-based ones for Leishmania quantification are more expensive 
and complex (additional procedure time and handling steps), but also more sensitive 
(226). In addition, there might be differences in the parasite load outcomes for DNA or 
RNA-based qPCR, therefore affecting decisions about the most efficacious compound to 
progress along the R&D pipeline. Indeed, during a comparison of the intralesional 
parasites after PM, AmBisome and Fungisome treatment, we observed a difference in 
absolute values for parasite load (DNA>RNA assay). However, the ranking order and dose-
dependent trends for these drugs were very similar among DNA and RNA-based assays 
(see supplementary material). This new qPCR method can be a tool in PD, immunological 
and diagnostic Leishmania studies. 
 A method for quantification of inflammatory cells and macrophages in CL lesions, based 
on anti-Iba-1 and H&E stains and computational image analysis (chapter 3.4.). This could 
be particularly useful in the study of wound healing agents and immunomodulators, alone 
or in combination with chemotherapeutics, in animal models of CL.     
 A murine model of local inflammation in the skin, the “pseudolesion”, clearly 
characterized in terms of histology and vascular permeability of the capillaries (chapter 
3.4). This could be applied as a research tool in further PK studies in CL, but also for other 
skin inflammatory diseases such as atopic dermatitis, psoriasis and cutaneous cancers.       
 
Figure 34 gives a potential screening cascade for drug development for CL focussing on PK 
and antileishmanial activity and shows where the new methods might be of use to support 
drug development.  
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Figure 34: Example of a screening cascade for CL drug development and where the new 
methodologies (red circles) could be implemented. qPCR PL: quantitate PCR to measure parasite 
load. #mΦ: image analysis to estimate the number of macrophages in skin tissue. SMD: skin 
microdialysis. 
 
 
5.3. New drug candidates tested for the treatment of CL 
 
Using the research methodologies described above, the efficacy and tolerability of the 
following three drug candidates were evaluated in animal models of CL:  
1. A combination of PM with CQ (chapter 3.1.). Despite initially promising in vitro results, 
no additional in vivo efficacy of the combination therapy could be observed compared 
to the drugs alone. This combination is therefore unlikely to be worthy of further 
investigation as a new CL treatment. Lysosomotropic such as CQ remain interesting 
research tools to investigate how the acid environment the phagolysosome affects 
cellular drug trafficking towards the parasite target.      
      
2. A multilamellar liposomal formulation of AmB (for IV infusion) called Fungisome®, 
already on the market in India from the company Lifecare Innovations (chapter 3.3.). 
We showed evidence for some - albeit low – in vivo efficacy against CL, but its narrow 
therapeutic index is a cause for concern. Originally targeted at the Indian market to 
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help overcome the high price and limited access of AmBisome® for the treatment of 
invasive fungal infections and VL, it remains currently unclear how relevant this 
liposomal AmB formulation could be in (M)CL therapy in Latin-America and the 
Middle-East. However, the evidence for drug accumulation in the skin might support 
a potential role for Fungisome in the pharmacotherapy of PKDL on the Indian 
Subcontinent. A topical Fungisome cream is also commercially available (227), which 
might be explored for treatment CL, MCL and PKDL.     
3. An oral drug candidate for VL from the non-profit public-private partnership DNDI, the 
nitroimidazole DNDI-0690. We observed excellent oral efficacy (ED50 and ED90 values 
of ~ 5 and 21 mg/kg, once daily for 10 days.) and no adverse effects for doses as high 
as 50 mg/kg in the L. major-BALB/c mouse model of CL. In addition, we found relatively 
rapid drug accumulation of DNDI-0690 in skin lesions within around 3 hours of oral 
dosing. Translational PK modelling and combining PK and PD (in vitro IC90, in vitro or 
vivo rate of kill) data could provide a basis to predict dose regimens that are efficacious 
during phase II and III trials. To estimate the actual success rate of DNDI-0690 in CL 
trials In humans, the following information would assist:  
 
o Efficacy and dose-response in other animal models of  CL caused by different 
species of Leishmania, for example, L. major-C57Bl6 mouse, L. mexicana-
BALB/c mouse, L. amazonesis-CBA mouse, L. braziliensis-golden hamster. 
Some researchers argue for performing final preclinical drug evaluations in 
non-human primate models because they best mimic the pathology and 
immunology of the disease in humans (158). We believe the choice for monkey 
models of CL is not justifiable for several ethical and financial reasons, as a 
combination of different rodent models, with their own strengths and 
weaknesses, could be used to answer important research questions about 
drug efficacy, PK and safety.   
o The preclinical toxicology of DNDI-0690 (LD50, LD90, NOAEL, LOEL) has already 
been characterized by DNDI. During the upcoming phase I trials, a special 
emphasis should be on testicular side effects: such issues caused a similar 
nitroimidazole compound with promising activity for VL (DNDI-VL-2098) to be 
discontinued. 
o Advanced PK/PD. For PK, the unbound concentrations over time of DNDI-0690 
in plasma and infected dermis after administration of different single oral 
dosing (for example, 5, 25 and 50 mg/kg) and repeated dosing (for example, 
10 x 50 mg/kg) could be determined (MD). In addition, in vivo drug levels 
surrounding host cells could be simulated using in vitro assays, to understand 
the cellular PK/PD relation between the intracellular DNDI-0690 levels to 
which the amastigotes are exposed to and antileishmanial activity. For PD, 
rather than relying solely on in vitro IC90 data (based on a single time point) for 
PK/PD modelling, cidal dynamics should also be investigated: the minimal time 
required to kill intracellular amastigotes at minimal (IC50), effective (2x IC50) 
and near-macrophage-toxic drug levels (CC90) (228). Moreover, in vitro rate of 
kill can then be compared to in vivo cidal dynamics derived from continuous 
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parasite load monitoring during treatment with reporter molecules. This could 
help compare and validate new research methodologies. 
o Mode of action studies. The following experiments could provide additional 
evidence that DNDI-0690 is a prodrug that exerts its antileishmanial effects via 
formation of reactive radical species: (i) a lack of in vitro and in vivo activity of 
synthetic DNDI-0690 analogues without the nitro-function and (ii) variable 
sensitivity of transgenic Leishmania over- or under-expressing specific 
nitroreductases to DNDI-0690 in comparison to that of the wild-type parasite.     
o Assessing the risk of emergence of drug resistance an important part of 
antimicrobial drug development. However, in CL, there is no evidence of drug 
resistance for the standard chemotherapeutics, in contrast to VL. In addition, 
because the nitroimidazole DNDI-0690 is most likely a prodrug (requiring bio-
activation in Leishmania by nitro-group reduction), the risk of drug resistance 
could be considered inherently low. Standard procedures to induce 
experimental resistance in vitro and in vivo upon repeated sub-therapeutic 
exposure cycles are available for VL (229, 230). When using similar strategies 
to asses the risk of drug resistance for DNDI-0690 in CL, the dermal drug 
concentrations we have measured at the infection site in vivo can guide 
researchers to decide on biologically meaningful drug exposure levels in vitro.      
o ADME and PK. In terms of metabolism, especially the induction or inhibition of 
hepatic enzymes and the potential drug-drug interactions. To create 
efficacious combinations of DNDI-0690 with one or more other drugs, it is 
important that the components of the combination are all present in the 
infected dermis in adequate concentrations at the appropriate time to exert a 
synergetic effect in therapeutic efficacy.  Again, understanding PK and PK/PD 
profiles can assist to here.     
 
Alternatively, the orally bioavailable compound DNDI-0690 might also be produced in a 
topical pharmaceutical formulation to provide a new local treatment for small, uncomplicated 
CL skin lesions. Topical delivery is suitable for small (molecular weight < 500 Da) and rather 
lipophilic drugs: DNDI-0690 does not violate these criteria. Assays to assess in vitro 
permeation, ex vivo skin disposition (using Franz diffusion cells/tape stripping) and in vivo 
efficacy (L. major / L. mexicana - BALB/c / C57Bl6 mouse models) could be used to evaluate 
drug penetration across the stratum corneum, with or without the presence of  chemical 
permeation enhancers such as DMSO, urea, polyglycoles or ethanol in the topical formulation 
(159). More advanced cutaneous drug delivery systems, including microneedles and 
liposomes, or physical methods such as sonophoresis, electrophoresis and iontophoresis have 
not been explored in CL (231).  
In conclusion, based on the previous toxicity and the new in vivo efficacy and skin PK data, 
DNDI-0690 is a promising oral drug candidate for the treatment of CL. However, attrition rates 
during clinical trials are high. It is therefore important to maintain a strong R&D pipeline with 
backup drug candidates and provide a direction for future drug development for CL.  
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5.4. Directions for future R&D for CL  
 
Drug development encompasses a wide range of approaches to find new medicines to treat 
human disease, including immunotherapy, nanomedicine, small molecules, biologicals, 
antibodies, gene therapy, recombinant proteins and drug combinations. We will here discuss 
the potential of liposomes and small molecules in the search of new therapeutics for CL, the 
two most relevant strategies in the frame of the thesis. 
Encapsulation of drugs into liposomes, small spherical vesicles composed of one or more 
phospholipid bilayers, is a popular and theoretically attractive strategy for the treatment of 
leishmaniasis. Liposomes are suited for macrophage-targeted therapy, due to improved 
efficacy, low toxicity, flexibility to modify surface molecules and preferential uptake by the 
Leishmania host cells (232). While the vesicles are rapidly being cleared by the liver and spleen 
(which is important for VL therapy), the remaining fraction that can penetrate into the skin is 
prone for uptake by the dermal macrophages (CL) (233). Studies described the successful 
treatment of experimental CL with various liposomal formulations of PM (234), SbV (235), MF 
(236) and AmB (237),  but none have looked into their skin PK. Using the L. major-BALB/c 
model of CL, our work showed that drug levels in the lesion after administration of liposomal 
AmB (AmBisome) were higher compared to those achieved by non-liposomal deoxycholate 
AmB and compared to those found in healthy, uninfected skin (chapter 3.2., 3.3, 3.4.). In 
addition, AmB concentrations at the infection site, therapeutic window and tolerability of the 
standard LAmB formulation AmBisome (Gilead) were superior compared to alternative 
Fungisome (Lifecare Innovations) (chapter 3.3).  Hence, encapsulation of old and new 
antileishmanial drugs in AmBisome-like liposomes could be a drug delivery strategy to target 
the dermal infection site.  However, despite a number of rational arguments to support the 
use of liposomes in CL therapy (see above), there are also major limitations. Intravenous 
administration of the drug formulations and thus hospitalization is required: liposomes do not 
address the medical needs of many patients with simple, uncomplicated CL. In the future, the 
currently still commercially unavailable oral (polymer-coating, microencapsulation (238)) or 
topical liposomes (ethosomes, transfersomes, ultra-deformable structures (239)) might be 
more patient-friendly treatment options. In addition, issues related to the high cost, stability 
in tropical climates, logistics and access to medicines makes one wonder whether liposomes 
are truly the best way forward to treat a disease affecting populations living in remote areas, 
poverty and conflict. 
Another strategy for CL treatment is based on classic small molecule therapeutics, without 
the use of nanocarriers. These remain the majority of medicines on the market today, many 
being instant-release tablets or capsules. Such drug formulations are typically simpler and 
cheaper to manufacture, but finding small molecule libraries with the right balance of 
lipophilicity, solubility, metabolism, protein binding and ultimately activity and safety has 
historically been a major challenge for the pharmaceutical industry (240). Our work has 
shown that the pathology of CL might present both opportunities and challenges to achieve 
adequate concentrations of small drugs into the skin, depending on both factors related to 
the drug and the disease (pathophysiology):  
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 Drug: For both liposomal and non-liposomal drug formulations of amphotericin B, 
drug concentrations after intravenous drug administration to infected mice were 
consistently higher in the diseased skin than in the healthy skin (skin homogenates). 
Yet for DNDI-0690, a nitroimidazole, the opposite trend was observed after oral dosing 
(MD). However, the different PK sampling methodologies make interpretation and 
direct comparison of these results difficult. In any case, both examples show that there 
are differences in drug distribution in the Leishmania-infected and the uninfected skin 
after systemic drug administration of murine CL. The impact of CL pathology on drug 
PK should not be ignored during the development of (pre)clinical dose regimens. If 
less drug reaches the infection site than assumed, parasites might be exposed to 
subtherapeutic drug levels, possibly leading to treatment failure or the emergence of 
resistance. On the other hand, if more drug accumulates at the target site than 
expected, cure of CL might be achievable at lower drug doses or shorter treatment 
durations, which is especially important for compounds with a narrow therapeutic 
index.   
 Disease: the CL-infection site is characterized by (i) increased vascular permeability 
and capillary leakiness of the dermal vasculature (chapter 3.4) (ii) a reduced barrier 
function of the epidermis and (iii) an aqueous environment in the oedema-filled 
dermis (161). Hence, the histopathology of CL might be exploited for facilitated oral 
or topical delivery of small molecules to the infected dermis. In contrast, destruction 
of blood vessels due to tissue necrosis or the formation of thick, impermeable lesion 
crusts could hinder such drugs to reach the dermal site of action. Differences in 
pathology between species, as shown for L .major and L. mexicana contribute to the 
complexity of the issue. We showed that histopathology and inflammation severely 
affect the PK of LAmB: AmB levels in the lesion depend on the disease stage when the 
drug is administrated (papule> initial nodule> established nodule). Matrix-assisted 
laser desorption/ionisation - mass spectrometry (MALDI-MS) is a powerful, yet 
unexplored technique to help to address such questions about the influence of 
pathology on PK and PK/PD in CL drug research. Recently, studies on Mycobacterium 
tuberculosis, a pathogen occupying a similar intracellular site as Leishmania, used 
MALDI-MS to evaluate the penetration of TB drugs into lung lesions and visualize 
therapeutic biomarkers (241, 242).  A similar approach could provide a basis to dismiss 
candidate compounds for CL with impaired or suboptimal drug distribution within skin 
lesions, granuloma and infected macrophages from the pipeline during the early 
stages of drug development.  
 
Figure 35 attempts to list the PK path that oral and topical drugs need to take to reach the 
parasites residing within dermal macrophages.      
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Figure 35: Opportunities (green) and challenges (red) along the pharmacokinetic path of oral (blue) 
and topical (yellow) drugs against CL. 
 
In overall conclusion, the currently available treatments for CL are not appropriate for the 
clinical needs of many patients; advances towards the discovery and development of new 
drugs has been disappointing in comparison to those for VL. To improve this situation, we 
believe the following challenges across the path from bench to bedside must be addressed:  
 Firstly and most fundamentally, to ensure sustainable funding and collaborative drug 
development efforts from industry, academia, NGOs and governments with a clear 
scientific strategy and a common target profile. Importantly, in case we manage to 
eliminate VL in the Indian subcontinent during coming years, before the development 
of a new medicine for CL, will we be able to maintain R&D interest for the non-fatal 
yet most common form of leishmaniasis alone?   
 Secondly, to continue and expand open access high throughput screening efforts in 
the public domain to discover new hits and leads with broad-spectrum activity (against 
different parasites and disease forms), especially those with dermal bioavailability 
after oral/topical administration and an inherently low risk for the emergence of 
antimicrobial resistance. 
 Thirdly, to establish and validate more powerful predictive models and related 
research methods to evaluate preclinical drug candidates, so that only those with the 
highest chance of exerting clinical efficacy against Old and New World CL are moved 
forward along the R&D pipeline.  
 Fourthly, to discover therapeutic biomarkers to indicate cure or the risk of relapse to 
assess the efficacy of drugs and/or combinations in high quality randomized clinical 
trials, as well as their effectiveness in routine practice.  
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 Finally, to overcome barriers to access, for example by drug donations or allowing 
generic drug manufacturing, so the new medicine is affordable and available to those 
who need it most, the patients. This is a complex and multifaceted problem in which 
governments, NGOs, academia, pharmaceutical companies, finance institutions and 
WHO all have a role to play.  
 
In relation to the third need, this PhD thesis provides a collection of research methodologies 
and strategies that could support and accelerate successful preclinical R&D for CL. Indeed, 
these have already proven useful to confirm the promising potential of a new oral drug 
candidate: DNDI-0690. We hope that it will be the first of many, as attrition rates in the clinic 
are high. A central message in this work about drug development for CL is that compounds 
should not be evaluated based on their in vitro or in vivo antileishmanial activity alone, but 
also on their combined ability to (i) penetrate into the infected dermal tissue underneath the 
skin lesions (ii) reach the intracellular pathogen within macrophages and (iii) rapidly exert 
their antimicrobial effects at these sites. By improving our understanding of the PK and PD 
properties of old and new CL drugs, to which the novel MD and qPCR methods provide a 
means, PK/PD can help to bridge translational gaps along the R&D pathway and ultimately 
bring new medicines to the clinic. We hope that the encouraging trend of collaborative drug 
discovery and development for NTDs in recent years also creates a momentum to continue 
our progress towards safe, effective and patient-friendly treatments for CL.   
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7. APPENDIX  
 
7.1. Networks, partners and institutes 
 
7.1.1. Euroleish  
 
 
 
The aim of the EUROLEISH-NET programme is to provide the selected candidates the tools to 
start and consolidate their careers in the field of infectious disease control and leishmaniasis 
in particular. The training programme will promote scientific excellence, multidisciplinarity, 
and autonomy to increase the employability of the researchers. 
The core of the training programme is the PhD research projects conducted by the 15 selected 
candidates and each supervised by two specialized senior scientists from two institutions. 
Additionally, the researchers will benefit from group coaching at regular intervals in a number 
of retreats  
·         Scientific excellence: the 15 PhD students will engage each in a three-year PhD research 
project linked to non-academic institutions (e.g. private sector and/or public-private 
alliances). All trainees will be hosted by centres of excellence for leishmaniasis research 
located in Europe. Researchers will develop their skills (i.e. laboratory, analytical, 
epidemiology, etc) under the supervision of two senior scientists from different institutions. 
The research projects aim to lead to a PhD award and a series of high impact scientific 
publications. 
·         Multi-disciplinarity: The PhD projects offered include basic, translational and 
implementation research projects, and this combination will allow for challenging 
interactions within the network. Individual research projects draw from different scientific 
disciplines (i.e. molecular biology and epidemiology, drug discovery, vector control and 
immunology). Researchers will be inducted into a large, diverse and global research 
community with a strong European basis and focused on a common goal, leishmaniasis 
control. During their training, all researchers will spend (1) at least 6 months in a non-
academic (e.g. SME, NGO) institution and (2) a minimum of 2-3 months abroad to conduct 
part of their project.  
·         Autonomy: Researchers will be encouraged to take responsibility on the design, 
development and management of their research projects in coordination with the 
supervisors.  
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This project has received funding from the European Union's Horizon 2020 research and 
innovation programme under the Marie Sklodowska-Curie International Training 
Network grant agreement No 642609. 
Extracted from: http://www.euroleish.net/about 
 
7.1.2. Pharmidex Pharmaceutical Services Ltd. 
 
 
 
Pharmidex provides translational solutions using its world-renowned expertise in 
CNS/oncology, drug discovery and ADMET/pharmacokinetics. Founded in the UK in 2002, 
Pharmidex operates in state-of-the-art facilities in London and Stevenage to provide high-
quality bespoke experimental data to support drug discovery and development. 
Extracted from: https://www.pharmidex.com/  
 
7.1.3. Institute of Hygiene and Tropical Medicine, Lisbon  
 
 
 
IHMT’s mission is the development of scientific research in Biomedical Sciences, Tropical 
Medicine and Public Health, and the development of cooperation and dissemination of 
information in the Portuguese speaking countries. Thus, IHMT (www.ihmt.unl.pt) is an 
important player in specific health issues and the only Portuguese institution dedicated to the 
study of health in those countries. Furthermore, IHMT offers clinical services to travelers and 
has reference laboratories for diagnosis of the so-called tropical diseases. 
Extracted from: http://www.ihmt.unl.pt/en/  
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7.1.4. Drugs for Neglected Diseases initiative 
 
 
 
Founded in 2003 to address the needs of patients with the most neglected diseases, DNDi is 
a collaborative, patients’ needs-driven, not-for-profit drug R&D organization. 
The vision: to improve the quality of life and the health of people suffering from neglected 
diseases by using an alternative model to develop drugs for these diseases, and by ensuring 
equitable access to new and field-relevant health tools. In this not-for-profit model, driven by 
the public sector, a variety of players collaborate to raise awareness of the need to research 
and develop drugs for those neglected diseases that fall outside the scope of market-driven 
research and development (R&D). They also build public responsibility and leadership in 
addressing the needs of these patients. 
The mission: 
 To develop new drugs or new formulations of existing drugs for people living with 
neglected diseases. Acting in the public interest, DNDi bridges existing R&D gaps in 
essential drugs for these diseases by initiating and coordinating drug R&D projects in 
collaboration with the international research community, the public sector, the 
pharmaceutical industry, and other relevant partners. 
 DNDi’s primary focus has been the development of drugs for the most neglected 
diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), 
leishmaniasis, and Chagas disease, while considering engagement in R&D projects 
for other neglected patients (e.g. malaria, paediatric HIV, filarial infections) and 
development of diagnostics and/or vaccines to address unmet needs that others are 
unable or unwilling to address. 
 In pursuing these goals, DNDi enables R&D networks built on global collaborations. 
While harnessing existing support capacities in countries where the diseases are 
endemic, DNDi contributes to strengthening capacities in a sustainable manner, 
including through know-how and technology transfers in the field of drug R&D for 
neglected diseases. 
 In order to address the evolving needs of public health importance and maintain 
DNDi’s commitment to delivering on the objectives of the current portfolio of 
diseases, a dynamic portfolio approach has been adopted. This enables DNDi to take 
on new disease areas with various operating models while completing objectives in 
current diseases. 
Extracted from: https://www.DNDi.org/about-DNDi/vision-mission/  
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7.2. Supplementary material  
 
7.2.1. DNA- and RNA- based qPCR results  
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Figure 36: Outcomes of the DNA- and RNA-based qPCR methods to quantify parasite load (see 
chapter 5.3) 
 
 The general trend in parasite burden is very similar for both qPCR methods among the groups: 
untreated negative control (-) > Fungisome (F) >AmBisome (A) > paromomycin positive control 
(+). 
 The absolute values in terms of parasite load are about a 100-fold higher for all groups for the 
DNA-based compared to the RNA-based qPCR. This is likely a consequence of the 1/100 
dilution step of DNA extracts that was needed for the DNA method to give robust, accurate 
and reproducible results.  
 
 
 
 
 
